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Background of EBM 
 
 
 A brief history 
 
The history of evidence-based medicine starts many centuries ago. The clinical 
trial can be traced back to biblical times, when around 600 B.C. Daniel of Judah 
compared the health effects of a vegetarian diet with those of a royal Babylonian 
diet. After ten days the men who had been eating the vegetarian diet looked 
healthier than those who had indulged on the royal delicacies. So the warden took 
away the delicacies and wine and gave everybody a diet of vegetables instead.1 The 
first scientific publications of trials appear in the 18th and 19th century. Concerned 
about the impact of scurvy on the lives of seamen, James Lind, a Scottish naval 
physician (1716-1794), carried out an experiment with twelve men. In pairs they 
were given six different dietary additions, including one with oranges and lemons 
(1753).2 Almost a century later, in France Pierre Charles Alexandre Louis (1787-1872) 
introduces his ‘numerical method’ (“la méthode numérique”) into diagnosis and 
therapy in order to “… ensure that all medical practitioners arrive at identical 
results.” His method of careful observation, systematic record keeping and rigorous 
analysis of multiple cases provided the foundations for modern clinical 
epidemiology.3,4 The study of the effect of bloodletting for treating pneumonia was 
first published in the 1828 issue of the French journal ‘Archives Générale de 
Médecine’ and in 1836 in an American scientific journal. In spite of the impressive 
results of both Lind’s and Louis’ work, it wasn’t until many years later that medical 
practice changed accordingly. Pierre Louis’ contributions to medical science were 
made possible by the developments of statistics and the theory of chance.5 He was 
a contemporary of the Belgian astronomer and mathematician Adolphe Quetelet, 
who was born in Ghent in 1796. Quetelet introduced mathematical concepts that 
had been developed in astronomy to the study of sociological and societal 
phenomena and thus paved the way for modern biostatistics. His concept of the 
“average man”, based on the Belgian census of 1829, is still applied in epidemiology 
today.6 The first record of a randomised clinical trial is attributed to Austin 
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Bradford Hill. Supported by the British Medical Research Council he performed a 
trial with streptomycin to treat pulmonary tuberculosis.7 However, it has been 
suggested that the roots of evidence-based practice lie in Chinese medicine. In the 
reign of Emperor Qianlong (1688-1766) a method known as ‘kaozheng’ (‘textual 
criticism’, or ‘evidential research’) was practiced that resembles modern day critical 
appraisal. It refers to an effort to establish the authenticity of the classical 
Confucian texts through rigorous methods.8 
 
In 1971 Archie Cochrane, a Scottish physician and epidemiologist, published 
“Effectiveness and efficiency: random reflections on health services”.9 In this now 
‘modern classic’ he introduces the notion that health care and health services must 
be evaluated on the basis of scientific evidence rather than on clinical impression, 
anecdotal experience, ’expert opinion’, or tradition. He suggested that, because 
resources would always be limited, they should be used to provide equitably those 
forms of health care which had been shown to be effective in properly designed 
evaluations. In particular, he stressed the importance of using evidence from 
randomised controlled trials (RCTs) because these were likely to provide much 
more reliable information than other sources of evidence.10 Although clinical trials 
had been around for several hundred years, it was Cochrane’s 20th century 
advocacy that focussed attention on their importance for health care. His plea for 
more randomised clinical trials also included improved accessibility of these trials. 
The case of diethylstibestrol (DES), a drug prescribed to women who threatened to 
miscarry, illustrated the need for a proposal for well designed RCTs and visibility of 
the results of these studies. The recommendations for use of DES were based on 
non-randomised studies, whereas available randomised trials did not show an 
effect. Despite these findings DES continued to be used.11 The harm of this practice 
inflicted on the treated women, their daughters and their offspring is now well 
known. Greater accessibility of the information at the time might have saved lives. 
On the other hand Cochrane recognized the need to critically summarize the 
results of available trials. His ideas inspired Iain Chalmers, a British obstetrician, to 
compile a register of perinatal trials that was published in an electronic format in 
1988.12 Following the success of this register in the field of obstetrics, the first (NHS 
funded) Cochrane Centre in honor of Archie Cochrane, was established in 1992 in 
the U.K.. The worldwide Cochrane Collaboration was launched a year later. The 
Cochrane Library, containing databases with controlled clinical trials and 
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systematic reviews and meta-analyses on treatments in all major fields of clinical 
medicine, is now a leading source of evidence for clinicians, guideline developers 
and health policymakers. The methodology for tracing, selecting, appraising and 
synthesizing all this evidence was established by David Sackett and the McMaster 




 EBM: revolution or evolution? 
 
The term evidence-based medicine (EBM) first appeared in the medical 
literature in 1992 in a paper by Guyatt et al.13 Fifteen years after its introduction it is 
widely known in the field of health care. The concept of EBM, defined by its 
founding parents as "…the conscientious, explicit, and judicious use of current best 
evidence in making decisions about the care of individual patients…”14, is taught in 
medical schools all over the world and is a popular topic of postgraduate courses. 
Practising EBM or evidence-based practice (EBP) involves a process of lifelong 
learning based on questions raised through encounters with patients. The core idea 
is that by relying on clinical practices that have proven to be effective and by 
eliminating ineffective ones quality of patient care can improve.  
 
EBM is rooted in clinical epidemiology and builds on the methodological 
concepts of this discipline. It is not new, but rather an evolution of existing 
concepts and research methods, “an extension of … clinical epidemiology with rich 
contributions coming from biostatistics….”15,16 The development of information 
technology in the past two decades paved the way for its rapid advancement and 
popularity. The introduction of computers supported availability of new and 
complex biostatistical techniques and greatly improved the possibilities for research 
and clinical trial methodology. In stead of spending many days (and nights) 
running statistical tests on the few computers available at universities, nowadays 
the results are instantly available to researchers at their desk. This has certainly 
resulted in an increase of the number of (published) RCTs that contribute to the 
evidence base of clinical medicine.17 
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Computer technology, and more specifically the internet, has at the same time 
had a revolutionary impact on the availability of information. It has empowered 
many users. A growing number of electronic journals and databases are available 
on the internet and health professionals no longer need to visit academic libraries 
or rely solely on the opinion of ‘experts’ in order to fill the gaps in their knowledge. 
Open access to clinical guidelines, but also to Medline, the indexing system of the 
U.S. National Library of Medicine, enables them to ‘check the evidence’ at home or 
in the consultation room. Access for professionals in developing countries could 
have a dramatic impact on the battle against inequity.18 Likewise, the internet 
fosters a new level of knowledge among patients, enabling them to have input into 
making decisions about their own health. This is changing the way patients and 
doctors interact and it provides opportunities for new partnerships.19-21 However, 
alongside with these promising developments, concerns rise about the quality and 




 Limitations of EBM 
 
The widespread attention on EBM has also triggered critical reflection. The 
notion of ‘evidence’ must be seen in the context of its biostatistical roots. Evidence 
of a treatment effect is not ‘proof of an effect’ in the legal sense, but rather a 
probabilistic likelihood.23 We can never be ‘sure’, but rather must be satisfied with 
estimates of effect and their accuracy. Only the p-value can help us cope with this 
uncertainty. There is a risk then that this p-value becomes a dogma, fostering the 
mistaken idea that a single number can capture both the long-run outcomes of an 
experiment and the evidential meaning of a single result.24  
By nature EBM builds on reductionistic thinking, reducing the nature of 
complex things like disease and its management to simpler and more fundamental 
things that can be investigated in controlled trials.5 Moreover, the results of clinical 
trials tend to be interpreted as if they represent some kind of universally valid 
biomedical law, in the same sense as the results of physiological experiments. 
However, this is inconsistent with the reality that the effects of interventions are 
often not the same in different populations. Pathophysiological reasoning that 
builds on the results of laboratory experiments and knowledge of physiological 
processes could be expected to fill this gap, but the theoretical concepts it produces 
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are not always translated into the expected outcome in patients. Both methods are 
fundamentally different and generate different kinds of knowledge. Neither one 
can substitute for the other. Therefore, Wiersma argues that the medical 
practitioner must balance both types of knowledge in a plausible way, creating a 
“medicine with two faces”.5 
 
The limitations of the process of evidence-based practice can be related to three 
main aspects.  
First, the RCT, the cornerstone of EBM, is the most suitable research design to 
answer questions about treatments, but not everything can be randomized and 
concerns about issues like safety of treatments or prognosis of disease cannot be 
studied in RCTs and require other study designs.25,26 In their definition of EBM 
Sackett et al acknowledge that (probabilistic) evidence from clinical trials alone 
cannot be sufficient to support decision making. They point to the need to 
integrate various kinds of medical and non-medical knowledge, like clinical 
experience and patient preferences.14 However, it is not clear what the value of 
other types of medical knowledge might be and how this integration must take 
place.27 Over the past years the methodology for performing and synthesizing the 
results of RCTs has been studied and established, but for non-randomized designs 
or observational studies there still is a long way to go.  
Second, the ability of EBM to answer questions about care for individual 
patients is limited. Participants of trials are often a selected group of relatively 
young and healthy patients with clear pathologies. In clinical practice, and 
especially in primary care, patients present with symptoms rather than diagnoses 
and have multiple possibly interacting pathologies. What to do with a diabetic 
COPD patient whose treatment with corticosteroids may benefit his COPD, but will 
interfere with glycemic control?  
Third, disseminating the evidence to health professionals poses problems. In 
spite of wide spread availability of clinical practice guidelines, evidence syntheses 
(e.g. the BMJ publication ‘Clinical Evidence’) and research findings through online 
databases (Pubmed), the gap between evidence and practice is still wide. It is clear 
that mere availability of evidence does not automatically result in evidence-based 
practice. Many other factors interfere with this process. At the moment we are still 
struggling to identify the best ways to transmit evidence and enhance uptake in 
clinical care.28-32  
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We should also be aware that the meaning of EBM as a label of high quality 
evidence may have been eroded. Since everybody can apply his own definition of 
‘EBM’, the label has lost meaning and can even be deceptive.33 Finally, critics point 
to the fact that evidence for the effect of EBM on patient outcome is lacking.34,35 
Most of the studies evaluating guideline implementation strategies report output 
parameters related to the process of care (proportion of patients screened or 
antibiotics prescribed, ….).31,36 Recently, a multinational cohort analysis showed 
that improved hospital management of patients with acute coronary syndromes 
based on evidence from RCTs has resulted in significant reductions in the rates of 
new heart failure and mortality.37 However, evidence on the effect of current 





Objective of the thesis 
 
In this thesis we take a closer look at the implementation of evidence in clinical 
practice. The goal of evidence-based medicine is to improve clinical performance 
resulting in better quality of care. However, ‘quality of care’ is a complex concept 
and may need more input than what evidence-based medicine currently offers. 
Perhaps we should look at it with a wider scope. The thesis departs from a 
comprehensive framework for understanding and designing strategies aimed at 
improving quality of care. The theoretical concept is adapted from the ‘Donabedian 
triangle’, a systems-based framework for studying health care, including structure, 
process and outcome.39 Various factors related to the structure and process of 
health care were added, thus creating a comprehensive framework that enables us 
to understand the complexity of changing physicians’ behavior in the quest for 
improving quality of care through enhanced uptake of findings from clinical 
research. When approaching this theoretical framework from a research perspective 
three different types of evidence emerge: medical, contextual and policy evidence. 
We argue that each of these three evidence types is needed in the quality debate. 
They are incorporated in an ‘evidence framework’ that could be useful for 
identifying gaps in the evidence and contribute to a better understanding of the 
determinants of patient care. In addition it could be helpful when designing and 
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evaluating interventions aimed at improving quality of care. In this thesis we focus 
on the usefulness of the ‘evidence framework’ as an instrument to structure 
evidence from research in relation to quality improvement. The papers presented 
in the thesis explore the three types of evidence in primary care. As primary care 
implies “…dealing with all health problems regardless of the age, sex, or any other 
characteristic of the person …”40 it is important to study the framework in a range 
of health issues. Therefore, our studies use different research designs and are 
performed in several domains relevant to primary care, such as upper respiratory 




 Medical evidence 
 
It goes without saying that reliable medical evidence is an indispensable 
support for clinical care. But evidence can either be ‘weak’ or ‘strong’ and it is 
important for clinicians to be aware of the strength of the evidence underpinning 
recommendations for practice. Therefore, in order to differentiate between weak 
and strong evidence a hierarchy of ‘levels of evidence’ has been created.14 These 
levels of evidence are based on the study design and the methodological quality of 
individual studies.41 In EBM evidence derived from RCTs is considered as the 
strongest. And in the same logic, the synthesis of RCTs in systematic reviews and 
meta-analyses provides the highest level of evidence for the efficacy of health care 
interventions. Evidence that is based on non-randomised or observational study 
designs has a lower ranking. Expert opinion represents the lowest level in the 
evidence hierarchy.14,41 Guideline developers use this information and combine it 
with a judgement about generalizability, applicability, consistency and clinical 
impact in order to create a link between the supporting evidence and a 
recommendation for practice. The strength of the recommendation is graded 
taking these aspects into account.41-43 Therefore, it is extremely important to 
evaluate the validity and reliability of the evidence underpinning practice 
recommendations. The Cochrane Library is historically and presently a leading 
source of synthesized medical evidence. We chose to take a closer look at 
systematic reviews in the Cochrane Database of Systematic Reviews. Various 
methodological issues can bias the results of reviews. An important aspect is 
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publication bias. Only including (published) trials that may be more likely to show 
results in favor of a new treatment and not including unpublished trials, could bias 
the pooled estimates of the meta-analysis.44,45 Cochrane reviewers are therefore 
encouraged to also search for unpublished material. We wanted to know if these 
extensive searches for trials that had not (yet) been available as a paper published 




 Transmission of medical evidence 
 
The EBM movement has made more evidence of higher quality available in user 
friendly formats, like clinical practice guidelines. Clear evidence-based guidance 
should be sufficient to convince physicians to adapt their performance accordingly. 
Then, why is it that we do not succeed in integrating this knowledge in the care for 
patients? An impressive number of studies conclude that implementing guidelines 
is difficult. The reasons for not following guidelines are multiple and differ among 
guidelines, health care settings and doctors, ranging from unfamiliarity with the 
contents to disagreement and difficulties with changing prior behaviors.28,46-48 
Could this be overcome by better implementation strategies? It is clear that merely 
distributing guidelines does not affect prescribing.32,49,50 In many European 
countries peer review groups or quality circles have become an important 
instrument for the improvement of quality of care.51,52 These small groups of 
physicians are based on voluntary participation and are dedicated to continuously 
assessing and improving their own patient care without interference of ‘experts’ or 
so-called ‘opinion leaders’ to guide the process. Mutual respect, commitment and 
continuity are thought to provide the strong base required for change.52 
Considering these characteristics they can play an important role in the 
implementation of guidelines. Several authors have made use of quality circles in 
designing guideline implementation studies, but mostly multiple sessions and 
presence of an ‘expert’ were involved. The evidence for the effectiveness of ‘pure’ 
(i.e. without external interference) peer group interventions as a tool to promote 
evidence-based practice is scarce.31 In this thesis we contribute to the evidence base 
on small peer group oriented implementation strategies. Like for the effect of 
treatments, the effect of interventions aimed at disseminating evidence or changing 
practice should be assessed by evidence-based methods. Therefore, we used the 
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design of a randomised controlled trial to assess the impact of discussing a new 
national guideline on the rational use of antibiotics in acute rhinosinusitis53 in local 
quality circles of primary care physicians. In our pragmatic trial we contacted the 
group moderator and provided written materials for use during the group sessions, 
but did not attend the meeting. The trial thus evaluates the actual potential of this 





 Contextual evidence 
 
Even if the ‘evidence’ is transmitted and understood, other factors may interfere 
in the decision making process and hamper implementation in patient care. These 
factors can be related to the patient, the doctor and the health care setting. In an 
observational study we focussed on one of these aspects of context, the doctor-
patient encounter, where clinical decisions are shaped and made. Internationally 
the impact of doctor-patient interactions on prescribing has been studied for 
respiratory tract infections in primary care. Several authors have pointed to the 
‘misunderstandings’ between physicians and their patients that result in 
inappropriate prescribing of antibiotics for acute respiratory tract infections.54-58 A 
better understanding of what patients expect and how they communicate this 
during the consultation could provide valuable clues to assist doctors in managing 
acute respiratory infections according to the guidelines, i.e. in general without an 
antibiotic prescription. In Belgium high antibiotic prescribing rates and growing 
antimicrobial resistance have put antibiotic prescribing high on the agenda.59 The 
Belgian Antibiotic Policy Coordinating Committee (BAPCOC) has published several 
guidelines on the management of acute infections in ambulatory care.60 Research 
on facilitating and impeding factors could contribute to effective implementation 
of these guidelines. Following the publication of a guideline on rational use of 
antibiotics for acute sore throat in 200161, we explored contextual factors that could 
influence guideline uptake in treating patients who consult their primary care 
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 Policy evidence 
 
Each encounter with patients is set in a health policy environment, which 
involves efficiency and equity. Efficiency deals with costs related to effect, the most 
efficient intervention provides a maximum of benefit for a minimum of costs. 
Equity refers to fair distribution of the available resources in an accessible health 
care system.  
In addition to implementation strategies aimed at physicians, such as the 
interventions in local quality circles, health policy regulations could play a role in 
shaping evidence-based practice. Scarce resources force governments and health 
insurers to look for strategies to control rising health care costs. Drug expenses are 
an important concern and initiate various types of policy regulations. In general, 
these regulations are inspired by cost-containment agenda’s. They are usually not 
directly linked to scientific evidence from clinical practice guidelines. However, 
they are potentially powerful instruments to change prescribing habits. We looked 
at the impact of reimbursement policies on physicians’ prescribing for acid 
suppressant drugs in Belgium over a period of nine years and how this relates to 









Outline of the thesis 
 
Chapter 2 presents a conceptual framework for the analysis of quality of care 
that draws attention to the need for evidence in three domains: medical, 
contextual and policy evidence. These three types of evidence are captured in an 
‘evidence framework’ that could be used as an instrument to structure research and 
to evaluate and design strategies aimed at improving quality of care. The 
subsequent chapters of the thesis explore by means of research in different 
domains how this evidence framework can be useful. 
 
In chapter 3 we focus on the nature of the available medical evidence. We take 
a closer look at systematic reviews and meta-analyses published in the Cochrane 
Library, a leading source of synthesized evidence. We demonstrate the pitfalls 
related to inclusion of unpublished data in systematic reviews.  
 
How to transmit medical evidence to physicians is dealt with in chapter 4. In a 
pragmatic cluster randomized clinical trial a strategy to promote uptake of a new 
guideline on acute rhinosinusitis is evaluated. The strategy makes use of local 
quality circles of primary care physicians that are a core feature of the continuing 
medical education systems in Belgium and many other European countries.  
 
Contextual evidence is explored in chapter 5. We report the results of an 
observational study in primary care that focuses on physician-patient 
communication during consultations for acute sore throat. It explores the patient’s 
perspective of his needs and how they are translated into hope for antibiotic 
treatment.  
 
How health care policy affects prescribing behavior of physicians is illustrated in 
chapter 6. We analysed national prescribing data for acid suppressant drugs in 
relation to specific reimbursement policies and publication of an evidence report. 
 
In chapter 7 we discuss our findings, summarize the implications for 
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In this chapter we present a 
conceptual framework for the 
analysis of quality of care. It shows 
the complexity of the 
determinants of quality and 
emphasizes that in order to 
improve quality of health care we 
need evidence derived from three 
domains: medical, contextual and 
policy evidence. These three 
domains are incorporated in an 
'evidence framework' that 
comprises the core of the thesis. 
The research papers explore the 
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Quality of care
Medical evidence provides 
information on the 'efficacy' of 
interventions; how well they 
work in the controlled 
conditions of a clinical trial. It 
is the cornerstone of evidence-
based practice and is 
indispensable for scientifically 
sound recommendations for 
clinical care. Therefore, 
medical evidence should be 
carefully appraised and 
selected. In this chapter we 
focus on the nature of the 
available 'medical evidence'. We 
take a closer look at systematic 
reviews and meta-analyses 
published in the Cochrane 
Library. We demonstrate the 
pitfalls related to the inclusion 
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What is already known 
 Including unpublished trials in systematic reviews and meta-analyses does not 
necessarily solve the problem of publication bias. 
 Inclusion of methodologically weak trials can bias the results of reviews and 
meta-analyses. 
 
What this study adds 
 Only a minority of Cochrane reviews include data from unpublished trials. 
 The methodological quality of trials that remain unpublished is unclear or weak. 
 Systematically searching for unpublished trials in reviews or meta-analyses may 
not be worth the effort. 
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Abstract 
 
Objective: To assess the value of searching for unpublished data by exploring the 
extent to which Cochrane reviews include unpublished data and by evaluating the 
methodological quality of unpublished trials. 
 
Design: Retrospective analysis of trials included in Cochrane reviews. 
 
Data sources: We screened all 2462 completed Cochrane reviews published since 
2000 in the Cochrane Database of Systematic Reviews Issue 3, 2006 for inclusion of 
unpublished data.  
 
Review methods: In a random sample of 61 reviews from 292 reviews (11.9%) that 
included references to unpublished trials we studied all 116 references in detail. Data 
on source of the unpublished trial, methodological criteria, population size, funding 
source and incorporation in the review were extracted. 
 
Results: References to unpublished trials make up 8.8% of all included trials in our 
sample. We found that 36.2% of the trials marked as “unpublished” have in fact been 
published. Allocation concealment was ‘adequate’ in 45.7% and 61.2% was double 
blinded or outcome assessor blinded. In 46.8% withdrawal rates were high ( > 20% ). 
Trials that were eventually published had larger mean population sizes (p-value 
0.026). A sponsor was reported for 60.3%, of which 88.6% was a drug company. 
Methodological quality and publication bias are mentioned in half of the reviews and 
explored in a third. Quality ratings did not have consequences for pooling since 82.8% 
was included in the review’s forest plots. 
 
Conclusions: Only a small proportion of Cochrane reviews include references to 
“unpublished trials” and many of these are eventually published. The truly 
unpublished studies are often of poor or unclear methodological quality. Therefore, it 
may be advisable to invest in assessment of trial quality and regular updating of 
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Introduction 
 
The Cochrane Database of Systematic Reviews (CDSR) is one of the most important 
sources of reviews and meta-analyses in the field of clinical medicine. The results of 
Cochrane reviews are consulted by clinicians, guideline developers and health policy 
makers and contribute to the growing body of “medical evidence”.1 Reviewers use a 
standardized methodology as described in the reviewer’s handbook2 that makes the 
review process and the synthesis of evidence transparent and increases the 
methodological rigor.3 Minimizing bias related to the studies that make up the 
review and the way these studies are collected is an important issue in Cochrane 
reviews. The Handbook states that, “A comprehensive search for relevant RCTs, which 
seeks to minimize bias, is one of the essential steps in doing a systematic review….”2 
Since studies with significant results (in favour of the new treatment) have a higher 
chance of being published4,5, this includes attempts to locate unpublished studies.2 
Excluding them can lead to exaggerated estimates of the effectiveness of an 
intervention in the meta-analysis.6,7  
Already in 1993 Cook et al discussed the controversies related to including 
unpublished data in meta-analyses.8 They point to the lack of information and/or 
sufficient methodological quality of these unpublished studies and recommend that 
both published and unpublished data should be subject to the same rigorous 
methodological evaluation. Presenting the results with and without inclusion of 
unpublished data in a sensitivity analysis could improve the quality of meta-
analyses.9 An HTA Report shares these concerns and mentions that by including 
(unpublished) trials of low quality bias could even be introduced, rather than 
prevented.10 
We wanted to know whether the use of unpublished material is a valuable 
contribution to Cochrane reviews. Therefore we explored the quantity and 





We retrieved all completed reviews listed in the Cochrane Library issue 3 of 2006 
from the Wiley InterScience electronic interface. In all reviews published since the 
first issue of 2000 we checked the reference lists for included unpublished studies 
(marked as “unpublished data only”). We focussed on the references to “unpublished 
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data only”, rather than additional data that are obtained from the authors of 
published papers and are marked as “published and unpublished data”. By means of 
computer generated random numbers we took a random sample of the reviews 
including unpublished data. We estimated that 20% of all reviews would be a 
sufficient sample size to provide relevant results. The reviews in the random sample 
were scrutinised for number and type of unpublished material. For each reference to 
an unpublished study we searched MEDLINE and Google Scholar (November 2006) in 
an attempt to locate formal publications of the trial in biomedical peer reviewed 
journals. We classified the trials for which we found a journal publication as 
published within or after the reported search period. The remainder of truly 
unpublished trials were categorized as reviewer’s own data, data from manufacturers, 
conference abstracts (available online or in journal supplements), dissertation or 
“could not be located”. For all trials labelled as “unpublished data only” we extracted 
the reported methodological quality for three items that are directly related to the 
control of bias (allocation concealment, blinding and withdrawals).11 We also 
extracted population size and funding source from the tables with characteristics of 
included studies. 
 
We used SPSS 12.0 to generate frequency tables and Pearson Chi-square tests with 
continuity correction to test for differences between proportions. We used ANOVA 
and t-test to test for differences between means. P-values < 0.05 are considered 
statistically significant. 
  




Figure 1: Flowchart of Cochrane reviews selected from all completed reviews 
published in the Cochrane Library Issue 1, 2000 to Issue 3, 2006. 
All completed reviews 
 
N=2462




Random sample of 284 reviews including references to “unpublished data only” 
 
N=61 reviews with 1316 references
References retrieved as paper  
published in a peer reviewed journal 
(42 references in 30 reviews) 
References not retrieved as paper  
published in a peer reviewed journal 
(74 references in 49 reviews) 
17 19 Within search period 
18 23 After search period 
ReviewReferenceTime of publication 
13 28 Data from manufacturer 
16 23 Conference abstracts 
3 4 Dissertation 
8 8 Not located 
9 11 Reviewer’s own data 
ReviewReferences Data source 
8 reviews excluded: only 
unpublished data 
116 references to “unpublished data only” in 61 reviews 
(8.8% of all references) 
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Results 
 
Reviews including unpublished references 
We identified 2689 completed reviews in the Cochrane Library 2006 issue 3, of which 
2462 have been published since 2000. References to unpublished data are included in 
292 reviews (11.9% of the reviews). (Figure 1) Eight reviews are entirely based on 
unpublished material and were excluded from this analysis since we were interested 
in the role of unpublished trials in reviews based on published and unpublished data. 
The remaining 284 reviews use data from both published and unpublished trials. In a 
random sample of 62 reviews (21.2% of all reviews including unpublished material) 
one review from the Cochrane methods group was excluded because it was not 
accessible to us. The mean number of included studies per review is 12.19 (SD 22.36) 
for all completed reviews, 20.88 (SD 29.36) for all reviews including references to 
“unpublished data only” and 21.57 (SD 28.78) in our random sample. The mean 
number of references to “unpublished data only” was 2.59 (SD 5.84) for all reviews 
that include this type of data and 1.89 (SD 1.68) in our sample of 61 reviews. 
Ninety-six references to unpublished trials (82.8%) provided data that were included 
in the forest plots of the reviews. Twenty unpublished studies were not presented in a 
forest plot. The reviews in our sample cover 32 of the 51 Cochrane Review Groups. 
Three groups are represented by five or more reviews (the Cochrane Airways Group, 
the Cochrane Dementia and Cognitive Improvement Group, and the Cochrane 
Stroke Group).  
 
Sources of references to “unpublished data only” 
We located publications in peer reviewed journals for 42 of the references marked as 
“unpublished data only”. Of these publications 19 had been published within the 
reported search period. Eight trials in the review were listed with a reference to a 
published paper, two to a paper in press and for another eight trials data were 
obtained from the author. The 23 papers published after the indicated search period 
were derived from a draft manuscript obtained before full publication of the study (9 
trials), as data from the authors (2 trials), data from manufacturers (5 trials), 
conference abstracts (4 trials) and data obtained through online accessible registers or 
reports (3 trials). The majority of the remainder of truly unpublished data were 
obtained from manufacturers or as conference abstracts. (Table 1) The trial sponsor 
was reported for 60.3% of the references (70/116); the vast majority of these trials were 
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sponsored by the pharmaceutical industry (62 of 70 trials). Only 8 studies report 
funding from non-commercial sources.  
 
Methodological quality  
Allocation concealment was rated adequate by the reviewers in less than half of the 
studies marked as “unpublished” (45.7%). (Table 2) Blinding of outcome assessment 
was reported for 13.0%. 48.3% of the trials were marked as double blind. Some studies 
(25 of 116) were also scored with another quality rating system: the Jadad-score10 in 22 
trials (12 trials had a score > 3) and in 3 studies in one review with the CCDAN-QRS11 
(a quality rating system of the Cochrane Depression, Anxiety & Neurosis Group). 
The withdrawal rate was reported for 62 of 116 trials (53.4%). Nearly half of these trials 
(46.8%) had withdrawal rates higher than 20% and in 14.5% of the trials more than half 
of the participants withdrew before the study ended. These high withdrawal rates 
were mainly reported in trials with psychiatric medication. One study on adherence 
to hormonal treatments had a withdrawal rate of 83%. 
 
We compared trials for which we could locate a publication to the truly unpublished 
trials and found that the unpublished trials were older than trials that were 
(eventually) published (F-statistic 3.626; p-value 0.001). Published trials had larger 
mean population sizes than trials that remained unpublished (591 vs 236; t-statistic 
2.30; 48.7 df; p-value 0.026). Trials with adequate allocation concealment were 
significantly larger than trials with unclear or inadequate blinding of allocation 
(mean population 513 vs 240; t-statistic 2.06; 60.1 df; p-value 0.044). Studies sponsored 
by manufacturers had significantly higher mean withdrawal rates than studies 
sponsored by non-commercial sources (t-statistic 2.026; 40 df; p-value 0.05). 
 
 
30         Chapter 3  ~  Medical evidence 
Table 1: Methodological quality, mean population size and proportion sponsored 






















































NR: not reported. 
 
Table 2: Methodological quality assessed by reported concealment of allocation, 
blinding and withdrawal rates of 116 references to “unpublished data only”.  
 
Concealment of allocation Number of references % of unpublished references 
Adequate 53 45.7 
Unclear 50 43.1 
Inadequate 2 1.7 
Not used 11 9.5 
Blinding   
Outcome assessor blinded 15 13.0 
“Double blind” 56 48.3 
“Single blind” 3 2.6 
No blinding 17 14.7 
Not reported 25 21.6 
Withdrawal rates   
<20% 30 25.9 
20-50% 23 19.8 
>50% 9 7.8 
Not reported 54 46.6 
  
Chapter 3   ~   Medical evidence          31 
Discussion 
 
Our study shows that searching for unpublished trials in Cochrane reviews does not 
give a high yield and that the methodological quality of unpublished trials raises 
concern. 
 
We found that only 11.9% of all recent Cochrane reviews included references to 
unpublished data. In an earlier literature review of 150 meta-analyses indexed in 
MEDLINE (1988 to 1999) 30.7% included unpublished data in their analysis.8 The 
attention to publication bias in the past decade and the recommendations to search 
for unpublished material9,13,14 apparently haven’t resulted in more frequent inclusion 
of unpublished data in Cochrane reviews. Recently, Egger et al found that funnel plot 
asymmetry did not disappear when unpublished trials were included, indicating that 
inclusion of unpublished data does not necessarily solve the problem of publication 
bias.10  
In our sample the proportion of unpublished trials included in the reviews is small. 
Only 8.8% of all references referred to “unpublished data only”. Considering the 
finding that eventually a third of these trials can be retrieved as full publications in 
journals, the actual proportion is even smaller (5.6%). Almost half of these 
“unpublished” references were available as a publication within the indicated search 
period. The other references were mostly presented to the reviewers as draft 
manuscripts, but it is not clear if these manuscripts had already passed the process of 
journal peer review. We found discrepancies in numbers of participants and events 
reported in the reviews’ forest plots and in the corresponding papers. Recently, Toma 
et al also reported discrepancies between conference abstracts and subsequent full-
length publications.15 Waiting for the published paper may therefore be a more 
reliable strategy.  
 
Why are so few unpublished trials included in Cochrane reviews? It is unlikely that 
the trials that have surfaced cover all the available unpublished data. More likely is 
that there is a large volume of trial data that is too difficult to find. Concerns about 
this led to the ‘Medical Editors Trial Amnesty’ in 1997, a call for all unreported trials to 
register on a website.16 This initiative had only limited success.17 The introduction of 
a prospective clinical trials registry listing all trials before they start recruiting patients 
is important for increasing accessibility.18,19 However, without an obligation to make 
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the results of these trials publicly available, valuable information will remain largely 
unknown to the scientific community. A “declaration of intent to publish all that is 
undertaken in the name of medical research…” is a first step to overcome some of 
these barriers.20 However, until this is endorsed by legislation21 the possibility remains 
that many trials will never be published. Moreover, the unpublished trials identified 
by the reviewers could be a selection of the available unpublished data. After all, the 
owners of the data (mostly drug companies) decide if and which data they pro-
vide.22-24 These data may be biased. Several authors have pointed to the relationship 
between drug company funding and study outcome25-29 or outcome of meta-
analysis6,30,31. In our sample of unpublished trials for which the funding source was 
reported the vast majority was sponsored by manufacturers. Several reviewers 
mention that authors or companies have failed to respond to their request for data. 
Some reviewers explicitly mention that they believe data have been withheld by 
manufacturers.32,33 This “donation bias” is a potentially serious matter. The cases of 
cyclooxygenase-2 selective inhibitors (rofecoxib and celecoxib) and of selective 
serotonin reuptake inhibitors in childhood depression show how detrimental 
withholding trial results from publication can be to public health.34-36 It shouldn’t be 
possible that authors, for-profit organizations or interest groups can grant themselves 
the right to deny the public the results of research that have implications for public 
health. Perhaps with the support and some pressure from regulating agencies, such as 
FDA, EMEA and WHO, research sponsors will show more social accountability. 
 
We also found that the methodological quality of the unpublished trials raises 
concern. For 64.3% of the trials the allocation concealment was either unclear or even 
inadequate or not used. Although 48.3% of the trials are reported as double blind, 
assessor blinding is only mentioned in 13%. Likewise, the high withdrawal rates are a 
disturbing source of bias. If the Cochrane reviewers are to realize the peer review for 
unpublished data, the clear lack of sufficient information on methodology in 
unpublished material seriously hampers the ability to assess its quality. On the other 
hand, the quality assessment does not seem to have any consequences for the meta-
analysis. The vast majority of unpublished references (82.8%) were included in forest 
plots, regardless of the methodological quality score. Only a few reviews (18%) 
actually incorporated these results in a sensitivity analysis or qualitative discussion. 
This is considerably less than the 50% found in a recent survey of 46 Cochrane 
reviews.37 This finding is a cause for concern about the validity of the results of 
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reviews. There is sufficient evidence that inadequate allocation concealment can lead 
to overestimation of the treatment effect or more positive outcomes.25,30,38 Likewise, 
insufficient blinding can bias the results of a meta-analysis.25,39 Therefore, including 
methodologically weak studies in meta-analyses may bias the results.  
 
In the publishing process journals editors play an important role in filtering the 
methodologically sound trials from the submitted papers. Also, wider adoption of the 
CONSORT statement40 can help improve reporting of methodology.41 If we could be 
sure that all the good quality trials are published, we wouldn’t need to be concerned 
about the unpublished ones. However, the publishing process itself could be 
responsible for the fact that some study results are not published. Peer review is open 
to arbitrariness and editors often prefer studies with clear (significant) messages.8,42 
Several authors have shown that a statistically significant outcome predicts 
publication and time to publication.43-46 The editors’ initiative to consider only 
registered trials for publication is important for transparency of the available 
research. However, it should be accompanied by a fair chance for all good quality 
trials to be published, regardless of the results. 
 
A limitation of our literature survey is that we explored only a sample of the 292 
reviews that use unpublished data. By taking a random sample we tried to minimize 
the chance of selection bias. The mean numbers of references and references to 
unpublished data in our sample were similar to the total group of reviews. We did 
not include the reviews that are entirely based on unpublished data. In this case the 
authors of the review perform the quality assessment and peer review. It would be 
interesting to investigate if the reported quality in these reviews differs from that in 




The question is if we would be missing the mark by not including unpublished data 
in meta-analyses. Our review shows that less than 10% of Cochrane reviews include 
unpublished data and that references to unpublished studies make up only a small 
proportion of all included studies. The fact that a third of these ”unpublished” 
references could be located as journal publications suggests that not including them 
in the review before formal publication would merely delay the evidence synthesis. 
The poor methodological transparency and quality of the trials that remain 
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unpublished is an important concern for the validity of the reviews. Therefore, it may 
be better to invest in improving (reporting of) methodological quality and regular 
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Quality of care
In this chapter we explore a 
strategy designed for the 
transmission of medical 
evidence to physicians. As 
clinical practice guidelines are 
the ultimate synthesis of 
selected and appraised medical 
evidence, we chose to evaluate 
the implementation of a new 
guideline on rational use of 
antibiotics in acute 
rhinosinusitis. In a pragmatic 
cluster randomized clinical trial 
we evaluated the uptake of the 
guideline's recommendations by 
local quality circles of primary 
care physicians, a core feature 
of continuing medical education 
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Quality of care
Contextual evidence provides 
information that helps us 
understand the effectiveness of 
interventions, i.e. the effect in 
'real life patients' in 'real life 
settings'. An important aspect 
of context that could influence 
decision making is doctor-
patient communication. In this 
chapter we report the results 
of an observational study in 
primary care that focuses on 
the communication between 
physician and patient during 
consultations for acute sore 
throat. It explores the patient's 
perspective of his or her needs 
and how they are translated 
into hope for antibiotic 
treatment. The potential 
impact of the results of this 
study on clinical care is 
illustrated in the editorial by 
John Hickner that is also 
included in this thesis. The 
editorial accompanied the 
paper when it was published in 
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Quality of care
The third domain of policy evidence 
provides information on efficiency (i.e. 
the best treatment for the best price) 
and on equity (fair distribution of care 
and resources to all citizens). 
Interventions that are efficacious (in 
clinical trials) and effective (in clinical 
care) also need to be cost-effective 
and efficient in order to be feasible 
and sustainable in health care systems 
that are bound by budgetary 
restrictions. Health insurers and 
policymakers issue policies, such as 
reimbursement regulations, in an 
attempt to contain growing expenses 
for medication. In this chapter an 
analysis of Belgian national prescribing 
data for acid suppressant drugs 
illustrates how the prescribed volume 
responds to specific reimbursement 
and shows that these policies can also 
have unintended effects. The fact that 
publication of an evidence report did 
not have a distinguishable effect on 
prescribing volume draws attention to 
the need to integrate medical and 
policy evidence when developing 
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In this chapter we discuss our 
research findings within the 
proposed framework of medical, 
contextual and policy evidence. 
We summarize some implications 
for the implementation of evidence 
in clinical practice and formulate 

















A conceptual framework for research 
 
 
David Sackett et al define EBM as "…the conscientious, explicit, and judicious use of 
current best evidence in making decisions about the care of individual patients…” and 
emphasize the need to integrate this evidence with clinical expertise and patient 
preferences.1 In a nutshell this description of EBM covers the entire process from the 
acquisition of evidence through clinical trials and synthesis of trial results to uptake by 
health care professionals, and to shared decision making with patients. It sounds 
attractive and logical. It would only be a matter of teaching the required skills to health 
care workers. Nevertheless, we now know and acknowledge that it is not so easy and 
straightforward. A linear mechanistic approach does not work. Clinical performance 
and medical decision making are complex processes influenced by many different 
factors.  
 
In this thesis we take our departure from a conceptual framework that may help us 
grasp the wide range of determinants and processes that play a role in improving 
quality of patient care (chapter 2). The picture is incomplete and there are numerous 
interactions between the different components, but it emphasizes the need to proceed 
beyond the linear approach to quality of care. It may help us understand why efforts to 
improve quality still fail to reach their goals. Why do doctors still prescribe antibiotics 
for self limiting upper respiratory tract infections? The evidence is available, as are the 
tools (guidelines) to bring the evidence to the providers. However, if the doctor fears 
losing the patient if he doesn’t give ‘value for money’ (characteristics of the health care 
system), or if he is not convinced that ‘watchful waiting’ is a safe option (belief of the 
individual professional), or if the patient believes that antibiotics are necessary to get 
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The conceptual framework also illustrates the rather limited role of evidence-based 
medicine. EBM is linked to the process of care and makes up the knowledge base of 
health care providers. Its role is restricted to improving the scientific rigor of guidelines 
and protocols and it aims to provide answers to problems in clinical practice. However, 
many questions still remain unanswered. EBM is a necessary condition for success, but 
not the only one. We argue that within the framework of quality analysis and quality 
improvement we need three types of evidence: medical, contextual and policy 
evidence. When making decisions in patient care we need to build on sound 
knowledge of the disease and its management (medical evidence), but we must also 
take into account the specific context of the health care setting and the encounter with 
patients (contextual evidence) and pay attention to efficiency and equity (policy 
evidence). These three types of evidence are incorporated in an ‘evidence framework’ 
that could be useful in the analysis and design of research on quality improvement 
strategies in primary care. The evidence framework comprises the core of the research 
presented in this thesis. Medical evidence is explored in chapter 3, contextual evidence 
in chapter 5 and policy evidence in chapter 6. The RCT in chapter 4 illustrates issues 
related to the transmission of medical evidence in the context of quality circles in 








The shaping of medical evidence 
 
Medical evidence derived from clinical trials is the core of evidence-based medicine. 
It provides information on the efficacy of treatments or interventions, referring to the 
effect in selected populations in specific settings and under controlled conditions. 
Synthesis of trials with the same research question increases the precision of the 
estimates of a potential effect. Evidence from systematic reviews and meta-analyses is 
regarded as high level evidence to underpin recommendations for clinical practice. 
Therefore, critical appraisal of the trials that are included in meta-analyses is an 
essential part of practising EBM. Our analysis of unpublished data included in 
  
Chapter 7   ~   General discussion and conclusion      61 
systematic reviews and meta-analyses published in the Cochrane Library raises 
concerns about the quality of these reviews. 
 
The finding that unpublished trials are of poor or unclear methodological quality is 
a threat to their validity, hence also to the validity of the reviews. Data from 
unpublished trials are often included in the forest plots and pooled with other studies 
to calculate an overall estimate of effect. Although reviewers mention the risk of bias in 
their review, only a few reviews report sensitivity analyses to explore this source of bias. 
Are we taking our quest for ‘high level evidence’ too far and pooling for the sake of 
pooling? The impact of trial quality on outcomes of meta-analysis has been 
documented. Inclusion of low quality studies can alter the interpretation of the benefit 
of an intervention towards a more positive effect.2 
 
Most of the unpublished trials in the Cochrane reviews were sponsored (and 
performed) by drug manufacturers. This also reflects a development of the past two 
decades. Performing an RCT has become a sophisticated and expensive undertaking. As 
a result independent institutions are often unable to fund their own research and turn 
to resources like pharmaceutical companies.3,4 The latter have fully embraced the 
methodology of the randomised controlled trial, especially since regulatory agencies, 
like FDA and EMEA, require such evidence in applications for registration or 
reimbursement of new drugs. The pharmaceutical industry has made the RCT and 
EBM into successful marketing tools. The label ‘evidence-based’ frequently appears in 
drug advertisements aimed at physicians and patients. This should be enough to 
convince them to prescribe or take the drug. The fact that these claims are usually not 
based on sound evidence5 is at most an academic debate.  
 
 However, more worrisome is the fact that the pharmaceutical industry now also 
seems to ‘master’ the available evidence base. Manufacturers can decide if and which 
data they present for publication or provide to reviewers. Evidence of the existence of 
this donation bias through selective release of evidence is demonstrated by the case of 
SSRIs, antidepressants for childhood depression, and the promotion of the 
cyclooxygenase-2-selective non-steroidal anti-inflammatory drugs (NSAIDs) rofecoxib 
and celecoxib. A meta-analysis of published trials reporting on the effect of SSRIs in 
depressed children and adolescents suggests a favorable risk-benefit profile. However, 
when unpublished data obtained from a review by the Committee on Safety of 
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Medicines are included, the results indicate that the risks (of serious events or suicide 
attempts) could outweigh the benefits.6,7 In the case of the cox-2-selective non-steroidal 
anti-inflammatory drugs, rofecoxib and celecoxib, data on safety were deliberately not 
reported in the published papers.8-11 Meanwhile rofecoxib, better known by its brand 
name Vioxx®, has been withdrawn from the market, leaving devastating effects on 
public health. Recent developments, like the introduction of prospective clinical trials 
registries listing all trials before they start recruiting patients are important for 
increasing accessibility and transparency.12-14 Making individual patient data available 
to reviewers could improve the clinical relevance of meta-analysis. For instance, a 
recent meta-analysis of individual patient data on the effect of antibiotics for acute 
otitis media in children, finally answered a burning question from clinicians.15 We now 
know which children have the best chance of benefiting from antibiotics.16 However, 
without an obligation and/or legislation to make the results of all trials available to the 
public, valuable information may still remain unknown.14,17-19 
 
The pharmaceutical industry currently also has a large input in the research 
agenda.20 As main sponsors of clinical research they largely decide what is studied and 
hence much of the available research is driven by commercial interests rather than the 
needs of clinicians and patients.21 Some ‘diseases’ have even been created or promoted 
in the media to provide markets for existing products, like ‘female sexual dysfunction’ 
or ‘restless leg syndrome’.22,23 The research agenda is further complicated by the fact 
that researchers who are linked to institutions that should be sources of independent 
research, like academic institutions, have alliances with manufacturers. Paradoxically, 
academics who are pre-eminently suitable for independent research must turn to 
pharmaceutical companies for support in order to continue their research programs. 
Awareness of the risks this poses to training and to independent research is urgently 
needed. In addition, policies to counter it must be developed.24,25 It also points to the 
need to consider investment of public resources in independent RCTs. 
 
Reporting of evidence is crucial in the era of EBM. Publication of research findings 
in biomedical journals and peer reviewed databases like the Cochrane Library is an 
essential link in the chain of evidence to the medical professionals. The role of medical 
journals in this debate therefore needs further attention. How journals compete to be 
the first to publish the results of large and prestigious trials and how this influences the 
accuracy and trustworthiness of reporting, still remains a ‘black box’. Two observations 
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reveal that ‘scientific objectivity’ of journals could be at risk. First, careful reading of 
abstracts of journal articles shows that reported results sometimes lack objectivity and 
that the authors’ conclusions are not always supported by all the results.26,27 A second 
indicator of the influence of competing interest in the publication process is the 
revelation of conflicts between editors of leading biomedical journals and commercial 
funding sources of those journals. Two published conflicts over editorial independence 
have resulted in the dismissal of the ‘dissident editors’.28-30 
 
We can measure the relevance of the results of clinical trials to clinical care by the 
reported outcome. But, how can we translate composite endpoints (such as endpoints 
composed of both fatal and non-fatal outcomes) to a tangible effect in individual 
patients?31 What to do with surrogate endpoints (e.g. serum cholesterol levels) that are 
frequently put forward as evidence for success, but often do not predict the true clinical 
effects of interventions (e.g. on mortality)?32 Patients are interested in the quality of their 
life, but this is seldom measured in clinical trials. Moreover, in an era of increasing 
multimorbidity the gap between single-disease oriented trials and the ‘real’ patient 
populations grows. 
 
Evidence-based medicine emphasizes the RCT as the cornerstone of medical 
evidence, but in order to answer other questions that are important to clinicians, such 
as the etiology or prognosis of a disease and the risks or harm related to treatments, 
other study designs are needed.33,34 In addition, some questions cannot be studied in 
experimental designs for ethical or practical reasons.35 For instance, placebo controlled 
trials in surgery are controversial36 and a proposal for a placebo controlled trial to study 
a treatment for meningitis will most likely not receive ethical approval. Likewise, we 
will never be able to prove with RCTs the effect of lifestyle factors such as smoking on 
lung cancer and mortality. Interventions that require long term guidance and follow-up 
(nutrition, behavior change) aren’t suitable for experimental designs either. 
 
Another issue is the magnitude or impact of the effect. Researchers and readers 
focus on ‘statistical significance’. We accept a probability of 5% that the results are due 
to chance (p < 0.05), but a p-value of 0.051 is dismissed as non-significant. On the other 
hand, the relevance of results that pass the statistical test of ‘chance’ can be inflated.37 
Like patients, doctors are looking for clear answers, certainties, a yes or no. Yet scientific 
research provides outcomes expressed as ‘relative risks’ or ‘relative risk reductions’, 
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resulting in ”more uncertain certainty”.38 Reported relative risk reductions (RRR) of 
treatments can be impressive, but also misleading, and interpretation is difficult 
without an accompanying absolute risk reduction.39,40 For instance, the CAPRIE trial 
shows that patients with recent cardiovascular events who were treated with 
clopidogrel had a significantly lower risk of a new event (defined as a composite of 
several events) than those treated with aspirin.41 The relative risk reduction reported in 
the abstract is 8.7%, but the absolute risk difference that can be calculated is only 0.51%. 
In clinical terms this means that 196 patients need to be treated for about two years 
with clopidogrel in stead of aspirin in order to prevent one (composite) new 
cardiovascular event. This puts the authors’ enthusiastic interpretation into a much less 
promising perspective. The number needed to treat (NNT) is a useful measure to 
estimate the impact in clinical practice, but unfortunately it is sometimes 
misunderstood42 and it has methodological drawbacks.43,44 
 
When interpreting trial results to clinical practice generalizability of the findings is 
important. How overzealous implementation can harm patients is illustrated by the 
events following publication of the RALES trial. The Randomized ALdactone Evaluation 
Study (RALES) demonstrated that spironolactone improves outcomes in patients with 
severe heart failure.45 These patients often also use ACE inhibitors and combination of 
both drugs can lead to life-threatening hyperkalemia. An analysis of population-based 
data showed that after publication of the RALES the rate of spironolactone prescriptions 
markedly increased in patients who were also treated with ACE inhibitors, including 
hospitalisation rates and associated mortality.46 In a trial patients are carefully selected 
and closely monitored, but in everyday practice this is usually not feasible. When 
translating trial results into clinical algorithms this should be taken into account. 
 
New systems of grading recommendations in evidence-based guidelines, such as 
GRADE, take many of the factors mentioned above into account.47-49 GRADE proposes 
to make sequential judgements about the quality of the evidence across studies, the 
critical outcomes, the overall quality of evidence across these outcomes, the balance 
between benefits and harms and finally the strength of the recommendations.49,50 The 
evidence quality is assessed by judgements of the study design (with the RCT at the 
top), the study quality (e.g. risk of bias by inadequate concealment of allocation or 
blinding), the consistency of the results across studies, and the directness (referring to 
the extent to which people, interventions and outcome measures are similar to those of 
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interest). RCTs are categorized as providing the highest level of evidence, but flaws in 
the methodology or important inconsistency can reduce their grade. On the other 
hand strong associations derived from observational studies (such as the association 





Conclusion and directions for future research of medical evidence 
 
The methodology of RCTs and the synthesis of evidence based on RCTs have 
evolved dramatically over the past two decades. The number of RCTs has increased 
and their methodological quality has greatly improved. Systematic reviews and meta-
analysis have resulted in better and more accurate estimates of the effects of treatments. 
Clinicians in the 21st century have access to an impressive and useful database of 
scientific evidence to underpin their clinical performance. However, many questions 
that arise in clinical care still remain unanswered, often because there is no commercial 
interest in such research. On the other hand, many clinical questions cannot be studied 
in RCTs and other research designs are needed. The methodology of non-randomised 
or observational studies and the synthesis of such studies have not evolved at the same 
pace as experimental designs and require attention in the near future. Considering the 
increasing influence of the pharmaceutical industry on both the funding of clinical 
research and the research agenda, there is an urgent need for more independent 
funding for research, including RCTs.  
Interpretation of the results of clinical trials in day to day practice is hampered by the 
strong emphasis on statistics and numbers. Medical evidence must be approached with 
a combination of reflective common sense and critical appraisal skills.51 It is important 
to pass on this attitude to students and foster it throughout the curriculum, specifically 
during the clinical training and in post graduate continuing professional education. 
This could be essential for successful implementation of medical evidence in clinical 
patient care. Studies have shown that EBM training integrated in the clinical internship 
and residency program has the greatest potential to improve knowledge and self-
assessed attitudes and behavior.52 Translation of these behavior changes into complex 
outcomes such as better patient care is not a linear process and may take time. Its 
potential to improve quality of care still needs to be assessed. 
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Transmission of medical evidence 
 
In a 1998 BMJ paper Bero et al reviewed the literature on interventions aimed at 
‘closing the gap between research and practice’.53 Nearly a decade later the ‘magic 
bullet’ to close this gap still hasn’t been found. In the mean time high quality and 
locally adapted practice guidelines have been developed and made available to health 
care professionals. Guidelines synthesize the evidence and translate it into practical 
messages that respond to questions arising in clinical patient care. They are a first and 
indispensable step in the process of transmitting evidence to clinicians. Many different 
types of interventions designed to introduce these guidelines to practitioners have been 
studied more or less extensively in various countries and health care settings. One of 
the most widespread instruments for knowledge transmission and behavior change is 
the local quality circle or peer review group. These small groups of peers (e.g. primary 
care physicians) working in the same local area are established as part of national 
continuing medical education (and accreditation) systems in many European countries. 
Nevertheless, their impact as an instrument to promote evidence-based practice has not 
been studied extensively.54,55 
 
We performed a pragmatic randomised controlled trial involving local quality 
circles of Flemish family physicians (chapter 4) and thus contribute to the evidence on 
the effect of small peer group interventions as a means to promote guideline uptake. 
Our trial shows that the current practice of a single group session on a new guideline 
without external interference does not result in a significant change in prescribing. A 
rational approach making use of a rational tool, i.e. an evidence-based guideline, is not 
followed by rational behavior. It also means that by merely financially supporting 
participation in quality circles, evidence will not automatically be integrated in clinical 
practice. Our research demonstrates the complexity of implementing medical evidence 
in clinical care. It also points to the need for research into other factors related to 
implementation, such as the context of peer review and physician-patient contact and 
the policy environment related to antibiotic use. 
 
The question remains how transmission of medical evidence can be optimised and 
how it can lead to the desired change of practice. Other studies with small group 
interventions suggest that by reinforcing group meetings with external support or 
multiple guided sessions a relevant improvement of prescribing can be achieved.56-58 
Interventions based on academic detailing have shown promising results.58,59 In 
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Belgium this has been proven feasible and acceptable in a pilot project60, but the 
impact on prescribing of implementation on a larger scale has not yet been evaluated. 
On the other hand, routine, untargeted outreach visiting may not be effective61, but 
combining these approaches in multifaceted interventions could yield more effect.58,59 
Perhaps, additional training of practitioners in communication skills can help 
overcome some (patient-related) barriers.59 However, it is impossible to cover the wide 
field of primary care with such intensive interventions, so priorities must be set. 
Moreover, multifaceted programs require additional human and financial resources 
and cost-effectiveness needs to be studied. 
 
The Belgian National Institute for Sickness and Invalidity Insurance (RIZIV/INAMI) 
has launched an information campaign in which they provide individual physicians 
with feedback reports of their prescribing profile.62 Physicians are encouraged to discuss 
these profiles with their peers in local quality circles. An evaluation of the impact of 
individual prescription feedback and consecutive national public campaigns aimed at 
both prescribers and the general public showed a declining trend in antibiotic 
prescribing.63 An effect of peer group discussions on antibiotic use in the local quality 
circles could not be demonstrated.63 Our trial confirms this finding. In other countries 
however, integrating prescription feedback in group meetings has shown potential to 
improve prescribing.64,65 Initiatives that support quality circles by providing critically 
appraised evidence, like Minerva, the Belgian independent journal for EBM66, could play 
a facilitating role. However, its impact on quality of care remains to be evaluated. 
 
EBM promotes a non-authoritarian approach to evidence, encouraging health care 
professionals to search for evidence from objective sources rather than from ‘experts’.1,67 
Yet, in spite of the success of EBM and the availability of ‘objective data’, these experts or 
opinion leaders are still important sources of information.68 The pharmaceutical 
industry often makes use of opinion leaders to promote their products. Strategies for 
implementing research findings that use local opinion leaders have shown to be 
effective in hospital settings, but the feasibility and impact in primary care is less  
clear.69-71 It may be worthwhile to further explore how these acknowledged ‘experts’ 
can contribute to passing on evidence-based information in primary care. 
 
Studying how interventions are received by health care professionals and the 
reasons why they do or do not change can reveal valuable clues for designing effective 
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interventions. Factors such as lack of time, support and resources have been mentioned, 
but also organizational issues related to (internal) communication, computer software, 
etc. play a role.72,73 In this context digital tools like PDAs (personal digital assistants) 
could be useful in supporting clinical decision making and promoting evidence-based 
practice. Their use has been studied in various clinical settings, both in medical 
training74, clinical practice and research.75 PDA users appreciate the practical 
applications and the rapid availability of evidence, but studies on the impact of digital 
decision support on the quality of care and on clinical patient outcomes are still 
lacking.  
 
In addition, we need to look at the evidence that is being transmitted. Problems 
with credibility and applicability of recommendations in guidelines have been 
mentioned by clinicians.76,77 Physicians are less compliant with recommendations that 
are considered controversial or require change of existing practice routines.78 Perhaps, a 
clear indication of the benefits to individual doctors of following the recommendation 
could enhance uptake. Availability of various different guidelines on the same topic can 
be confusing and calls for guidance from credible evidence-based institutions.79 The 
finding that most of the variation in prescribing between European countries could be 
explained by the national setting points to the importance of structural factors to 
guideline adherence.80,81 The North-South axis in antibiotic prescribing and resistance 





Conclusion and directions for future research in transmission of 
medical evidence  
 
The search for effective strategies to transmit medical evidence and evidence-based 
guidelines as a translation of evidence to clinical practice is still open. Our pragmatic 
trial shows that we should not rely on the existing local quality circles the way they 
function at present. In spite of the vast amount of literature on implementation 
strategies, many gaps in our knowledge remain. Implementation of evidence rests on 
processes that are studied in behavioral science and designing interventions therefore 
requires a multidisciplinary approach. We need to know more about the process of 
knowledge adaptation and how it is linked to the limitations of medical evidence, to 
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the context of health care and to the policy environment. When designing 
implementation strategies we can build on the instances that have been studied and 
published. However, local contextual and policy related factors should also be taken 
into account. Instead of looking for the one magic bullet, tailoring strategies to each 
specific topic, target group, time frame and context, followed by continuous evaluation 







Medical evidence derived from clinical research provides information on ‘efficacy’, 
the effect of an intervention in a controlled setting for a carefully selected group of 
patients. However, in reality patients in primary care are a mix of people with various 
biopsychological, cultural and socioeconomic backgrounds, who present with 
complaints rather than a diagnosis and often have more than one condition. They 
consult doctors with specific competences (e.g. in communication), beliefs and 
empathy. Moreover, without the careful follow-up of a trial setting, they are much less 
adherent to the prescribed treatment. All these factors make up the context of clinical 
care and contribute to the ‘efficacy of interventions in real life’, i.e. the ‘effectiveness’. 
Information from contextual evidence helps us understand the gap between ‘efficacy’ 
and ‘effectiveness’. This is what clinicians really need. It answers their most important 
question: ‘How will it work for my patients in my practice?’ 
 
In an observational study we explored contextual evidence in patients consulting 
their primary care physicians for an acute sore throat (chapter 5). Physicians often 
mention patient pressure for an antibiotic prescription as a reason why they do not 
adhere to guideline recommendations. Our study shows that an antibiotic prescription 
is not necessarily the patient’s main concern and that adequate analgesia may be a 
more important reason for seeking medical care. It suggests that patients who hope for 
an antibiotic may in fact want a treatment to alleviate pain. Patients may feel that 
antibiotics are the best treatment for pain in acute sore throat. Communicating with 
patients about their needs and potential misconceptions, and taking their ‘health 
 
70       Chapter 7  ~  General discussion and conclusion 
beliefs’ into account, could help remove this obstacle to evidence-based prescribing of 
antibiotics. 
 
Communication between physician and patient is a prominent aspect of context 
that is directly linked to the process in the theoretical framework (figure 1 in chapter 2). 
Although there is evidence of the impact of doctor-patient communication on the 
process and the outcome of health care interventions, we are still far from 
understanding how, when or why it works.83 Several other factors related to attitudes 
and beliefs about disease and well being complicate the picture. Very little is known 
about the effect of patients’ personality traits on outcome in medical conditions. By 
reducing ‘subjects’ (patients) to ‘objects’ that are studied in trials we could be missing 
important clues. Our study, like another cross-cultural study84, suggests that some 
patients have an inaccurate idea about the effect of antibiotics. This has been shown to 
influence prescribing.85 What about the doctors? How do they perceive the available 
evidence? Research on this issue is scarce, but a defensive attitude has been linked to 
overprescribing of antibiotics.86 Some studies on physicians’ attitudes towards evidence-
based medicine show that primary care physicians are concerned about the credibility 
and trustworthiness of available evidence.76,87,88 The discrepancies between the Belgian 
national consensus report on rational use of antibiotics for acute respiratory tract 
infections and the evidence-based guidelines of the scientific associations illustrate how 
this issue may influence acceptance and transfer of evidence to professionals. The jury 
of the consensus conference failed to reach an agreement on several issues regarding 
the management of acute tonsillitis or acute otitis media, in spite of the fact that the 
guidelines offered an evidence-based choice. When the jury report was published in 
June 2002 it was accompanied by a commentary from the organizers of the 
conference.89 The organizing committee explained that the differences between the 
jury report and the guidelines could be attributed to the methodology of the consensus 
process.89 This allows the jury to take the current clinical practice in Belgium into 
account when formulating their conclusions. Possibly, the jury was reluctant to 
formulate recommendations that differ from current practice and could create 
confusion. As a result they published recommendations that were based on ‘expert 
opinion’ rather than medical evidence.  
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More questions arise on the impact of cultural factors. Deschepper et al have 
demonstrated how two culturally close communities in Flanders and a neighbouring 
province of the Netherlands, differ with regard to disease labelling, coping strategies 
and attitudes towards antibiotics.90 On the Dutch side of the border patients with 
symptoms of a cold say they have “a flu” for which they do not seek medical care. On 
the other side Flemish patients have “bronchitis” and consult their doctor, who usually 
prescribes antibiotics. However, physicians nowadays face much larger cultural 
diversity. In an increasingly multicultural society health care professionals encounter 
patients from a large variety of cultural backgrounds with disease concepts, health 
seeking behavior and communicative approaches that are very different from their 
own and for which they are not properly prepared. They are challenged to apply 
ethnically sensitive strategies, but the underpinning knowledge is currently lacking. 
Likewise, the messages of public campaigns, such as the one on rational use of 
antibiotics91, may even have adverse effects in certain populations. How to adequately 
deal with these issues in the education of health care professionals and in the 
organization of care are intriguing challenges for research and for the design of 
implementation strategies. 
 
A frequently encountered problem, especially in primary care, is the fact that real 
life patients usually don’t fit the available evidence. Participants in trials are a selected 
and preferably homogeneous group with a clear diagnosis, whereas primary care 
patients mostly present with symptoms.92,93 Moreover, the growing population of 
elderly patients often has multiple diseases, even without a common biological 
basis.94,95 Studies including elderly patients are still very rare. Questions about the best 
available treatment for these patients often remain unanswered. Likewise, there is a 
lack of research on effective treatments for children. The ethical issues concerned are 
subject of ongoing debate.96,97 
 
Another issue determining the effectiveness of interventions is patients’ adherence 
to treatment. A WHO report estimates that adherence to long-term therapy for chronic 
illnesses in developed countries averages about 50%.98 This is known to most physicians 
who acknowledge that it hampers the effectiveness of secondary (and tertiary) 
preventive treatments, such as lipid lowering drugs, antihypertensive or antidiabetic 
drugs. However, they may assume that their patients will do better if they are faced 
with a life threatening disease, such as cancer. A recent database analysis of women 
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who were treated with tamoxifen for breast cancer shatters this illusion. It showed that 
adherence to tamoxifen was lower than previously reported in trials and that non-
adherence was as high as 35.2% after 3.5 years follow-up.99 A subanalysis of the CHARM 
study with chronic heart failure patients elegantly illustrates the importance of 
adherence to health. High adherence, even to placebo, resulted in a 35% lower mortality 
than low adherence.100,101 A meta-analysis of observational studies confirms this 
finding.102 Adherence might be a surrogate marker for overall healthy behavior. Because 
of the importance of non-adherence to the ‘effectiveness’ of medical evidence in clinical 
practice, it deserves more attention. Non-adherent patients should be considered a high 
risk group and require more attention and careful follow-up. Instruments to identify 
these patients need to be developed and studied.  
 
Other definitions of ‘contextual evidence’ can be found in the literature. Sometimes 
it is linked to data from qualitative research. In World Health Organization reports 
contextual evidence can refer to additional data, such as community health statistics, 
that support a case or describe a situation. In this thesis the concept of contextual 
evidence is not confined to a particular research method (such as qualitative research), 
nor to specific types of data (such as population statistics). It comprises information 
derived from various sources and through diverse research methods that can help us 





Conclusion and directions for future research of contextual 
evidence 
 
Medical evidence of ‘efficacy’ derived from clinical trials must be supplemented by 
evidence on contextual factors. Addition of contextual evidence to medical evidence 
translates ‘efficacy’ (derived from the ‘artificial’ setting of clinical trials) into 
‘effectiveness’ (the impact in daily life with ‘real patients’). Clinicians need information 
on effectiveness before they can apply research findings to day to day practice. Our 
research suggests that patients’ beliefs and expectations about antibiotics can play a role 
in rational prescribing for respiratory tract infections. It is possible that this is also 
important in other pathologies and domains of medical care. This requires further 
research. The influence of cultural factors is an increasingly important challenge. We 
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should learn more about the interactions between diverse culturally defined concepts 
of illness and health in order to develop educational and organizational interventions 
that can adequately address the identified needs. Patients’ adherence to treatment is an 
important issue in an ‘era of chronic diseases’. In order to improve quality of care in the 
21st century the focus on medical evidence must be widened to include evidence on 







In this thesis we have shown that information on the ‘efficacy’ of interventions that 
is based on sound medical evidence is the primary requisite for evidence-based 
practice. It should be augmented by evidence from the context of day to day practice 
that contributes to understanding the ‘effectiveness’ in real life. In a world with 
unlimited resources this would be sufficient to make implementation of evidence in 
clinical practice possible. However, all health care systems struggle with methods to 
control increasing expenditures and to ensure accessibility to all citizens. Therefore, 
‘efficiency’ and ‘equity’ need to be considered as well. Health policies, including those 
regulating reimbursement for medication, can be powerful drivers of physicians’ 
prescribing, at least on the short term. These policies are usually inspired by cost-
containment concerns and it is not always clear if this complements the principle of 
rational evidence-based prescribing. Our analysis of national prescribing data for acid 
suppressant medication in Belgium shows that indeed physicians’ prescribing responds 
to reimbursement policies. These policies however, do not discriminate between 
rational and irrational use of medication and therefore cannot be considered as 
sufficient to improve quality of care. On the other hand, the clinical practice 
recommendations that were published during the observed period did not have any 
noticeable impact on prescribed volumes.  
 
We have learned several things from this analysis. First, it shows that although the 
policies may have resulted in relevant savings for the health care budget, the 
contribution to public health is still questionable. Cost-containment through a policy 
favoring reimbursement of a cheaper product does not imply an increase of ‘efficiency’, 
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which refers to the best treatment for the best price. Still, many people who do not 
need the treatment or who would be better off with another intervention could be 
taking the drugs. Hence the resulting consumption remains inefficient. Second, it is not 
clear if these policies maintained or enhanced ‘equity’, referring to equal access to 
effective and efficient health interventions for those who may need or benefit from it. 
Are those who would benefit from the treatment taking it? Facilitating access to 
cheaper products does not lead to improved uptake, especially in resource poor groups 
in the community. The latest policy in our analysis that reintroduced an endoscopic 
examination as a condition for reimbursement of all proton pump inhibitors implies a 
visit to a gastroenterologist. And this may be an important barrier to adequate care for 
the underserved. Willems et al have shown that besides financial constraints, various 
other factors related to the individual as well as the health care system co-determine 
utilization of health services by the underserved.103  
 
The paper in chapter 5 also points to the importance of structural factors related to 
regulations as a potential barrier to rational prescribing. 40% of patients with a sore 
throat contact their physician to obtain a note for sick leave from school or work and 
thus ask him to legitimise their illness. Along with the note often goes a prescription. 
Countries where sick leave is legitimised by an external controlling organisation and 
not by the primary care physician, such as the Netherlands, have lower antibiotic 
prescribing rates.82 We argue that all these issues should be taken into account in the 
design of health policies and health systems. 
 
The conceptual model for decision making in health policy by Dobrow et al 
includes the issues mentioned above and fits in our framework (chapter 2). They 
approach implementation of evidence from the policymaker’s point of view and 
describe three important questions about interventions that need to be addressed by 
policymakers: effectiveness, appropriateness and implementation.104 
 
The first question, “will it work?” refers to efficacy and requires input from medical 
evidence. However, the available evidence is usually based on trials including selected 
groups of patients and it is not so obvious that evidence showing benefit to groups of 
individuals will have the same impact on communities.105 In addition, the effect of 
interventions between communities may differ. A health education method that is 
effective in a risk-averse community may have the opposite effect in a risk-tolerant one. 
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Likewise, it is unclear if expanding the current recommendation for an annual 
influenza vaccination in high-risk groups to other populations like schoolchildren will 
result in benefits at the public health level.106 
 
Although the available evidence base may be the same for policymakers in different 
countries, this does not result in policies that are the same across nations and regions. 
Policymakers have other concerns than clinicians and interpret the evidence in a 
societal context. This leads us to the second question, “should we do it?”. It deals with 
the appropriateness of the intervention in the specific national or local setting. It 
involves human, financial and technological resource capacity and reflects whether an 
intervention is feasible or practical in a specific context. Cost-effectiveness is important 
at this stage. At the same time it refers to the priorities that need to be set in each 
society. Should we invest in new treatments or technologies or rather in the promotion 
of preventative care such as smoking cessation or increased physical activity?107 Given 
the financial constraints policymakers face, the issues of efficiency and equity need 
careful consideration at this stage. Maynard argues that, “If evidence-based medicine 
and the individual ethic are allowed to determine treatment choices, resources will be 
used inefficiently and unethically”.108 He illustrates how economic analyses can 
contribute to this debate. Assume there are two treatment options, treatment A leading 
to five years of good quality of life survival and option B leading to ten years. An 
obvious and evidence-based choice would favor option B. However, introducing the 
costs of each of these options may change this preference. Suppose the cost of option A 
is estimated as 1,500 Euro, while option B costs 7,000 Euro. With a limited budget of 
70,000 Euro option A would be the preferred treatment, as it can lead to 133 more years 
of good quality life. Thus, from a population perspective, a physician prescribing option 
B uses resources inefficiently, depriving other patients of care from which they could 
benefit.108 
 
The equity debate also puts EBM in a wider perspective and draws attention to 
issues behind the apparently medical question. For instance, is preventing falls in older 
people an exclusively medical problem that should be addressed by clinical research? 
By focussing on the effect of medication to increase bone mineral density or on the 
effect of muscle strengthening exercises in order to improve mobility, we could be 
overlooking societal roots of the problem. If the streets and sidewalks are not safe to 
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walk on, mobility will remain a problem. This requires input from other disciplines 
that are traditionally not consulted by health care professionals. 
 
In order to provide policymakers with ‘tailored’ evidence summaries and cost-
effectiveness assessments many countries have established advisory institutions, such as 
the National Institute of Clinical excellence (NICE) in the U.K., the Health Council of the 
Netherlands (Gezondheidsraad) and the Belgian Health Care Knowledge Center 
(Federaal Kenniscentrum). They have become valuable sources of ‘objective’ evidence 
for policymakers, but are currently facing increased pressure from various stakeholders. 
A recent example illustrates how this pressure can shape outcome of evidence 
assessments. The first NICE guidance on the use of cholinesterase inhibitors for 
Alzheimer’s disease (2005) advised against the use of these drugs. Following the strong 
criticism by stakeholders, including patients with the disease and doctors working in 
the field, that the drugs may be effective for certain groups, NICE asked drug 
companies to provide evidence to this claim. As a result NICE revised its guidance, 
which greatly pleased patients and manufacturers.109 Considering this procedure of 
looking for evidence to fit the guidance and taking into account what we know about 
the risks of digging for unpublished evidence, we can question how ‘objective’ this 
revised guidance is. The merit of using consumer groups to support claims and pressure 
politicians has also been discovered by pharmaceutical companies. Policymakers 
sometimes face difficult dilemmas. How strong should the evidence be in order to 
outweigh the impact of groups of determined consumers with petitions on your 
doorstep? 
 
Finally, the third question points to actual implementation, “how do we do it here?”. 
This should build on evidence of the effectiveness of policies, but also of the harm 
inflicted by the introduction of specific policies.110 Some interventions may increase 
health inequalities. For instance, the pay-for-performance program that was introduced 
in the U.K. in 2004 paid general practitioners according to the proportion of patients for 
whom they achieve specific targets.111 An evaluation of the program revealed that some 
practices attained high levels of achievement by excluding large numbers of patients, 
raising questions about equity. Were ‘difficult’ or less compliant patients simply left out? 
This type of evidence is often lacking and deserves more attention. As Woolf states, 
society devotes most of its resources to develop and promote new drugs and 
technologies (predominantly through the pharmaceutical industry) and spends 
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relatively little on delivering the right care to the right patients at the right time.112 He 
calls for more research on improving health care systems. He illustrates how small 
improvements in care delivery can outweigh the benefits of small increases of efficacy 
of interventions. The greater the gaps in delivery, the more the efficacy of the 
intervention must be increased to make it more beneficial to public health than 
improving uptake of the intervention. WHO also recognizes the need for more health 
systems and health delivery research in its 2004 ‘Mexico Statement on Health Research’, 
with special emphasis on the needs of developing countries where resources are often 
insufficient to serve the most basic health needs.113 
 
The results of our analysis of national prescribing data and the reflections 
mentioned above make a strong case for more dialogue between policymakers, 
clinicians and researchers.114 They each have different goals and starting points, but will 
benefit from mutual understanding and collaboration.115,116 Policymakers could be 
more transparent in their ideologies and decision making process, but researchers need 
to acquire more understanding of the policy process. For research to have an impact it 
must target the values of policymakers, but in order to be relevant it must meet the 
needs identified by clinicians. A dialogue could also result in promoting and sponsoring 
research into issues that may be of little commercial interest, but are nevertheless 
relevant to society as a whole. This would also increase the social relevance and 




Conclusion and directions for future research of policy evidence 
 
Improving quality of care needs the input of efficiency and equity in addition to 
efficacy and effectiveness. Policy evidence therefore should be an integral part of the 
analysis and design of interventions to improve quality through implementation of 
evidence. Health policies that are inspired only by cost-containment agendas may 
succeed in saving costs but cannot be considered as efficient or equitable interventions. 
There is a growing need for policy evaluation research and health systems research that 
could guide policymakers in designing effective, efficient and equitable policies. A 
dialogue between policymakers, clinicians and researchers could assist in determining 
priorities for research and in designing policies that are based on solid clinical evidence, 
are appropriate to the individual setting and will be implemented by clinicians in 
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patient care. Consensus should not be the aim of this dialogue. Policy regulations 
should rather be designed according to an evidence-based methodology with an 
appropriate sequence. Ideally this starts with researchers formulating policy advice that 
is based on medical, contextual and policy evidence. Stakeholders must use this 
evidence to justify their positions. Then, policymakers must value the societal relevance 
and economic feasibility and define transparent and evidence-based priorities in 
accordance with general policy objectives. Likewise, guideline developers must also 
take the health policy environment into account to ensure that clinical practice 
guidelines are feasible in day to day practice. Finally, clinicians and other actors in the 
field of patient care, including patients, should take care of implementation at the 
practice level. Integrating medical and policy evidence could be a more effective and 
efficient way to achieve implementation of evidence in clinical practice and result in 










The conceptual framework presented in chapter 2 shows that improving quality of 
care requires input from different angles related to both the structure and the process 
of care. It explains why availability of evidence does not automatically result in 
evidence-based practice and better patient outcome. Interventions aimed at changing 
physician behavior therefore, must take several things into account. The ‘evidence 
framework’ can be useful in the analysis and design of research in this domain. Medical 
evidence from scientific studies provides the base for recommendations to improve 
quality of patient care, whereas contextual evidence adds clues for successful 
implementation in day to day practice. Policy evidence introduces the elements of 
efficiency and equity. In this thesis we illustrate that the proposed evidence framework 
can be useful in the analysis of determinants of quality of care. It can help us 
understand some factors related to the implementation of evidence and can guide 
further research. It is clear that translating knowledge into change is a complex 
undertaking. There is no ‘magic bullet’ to bend physician behavior towards evidence-
based practice as practice is influenced by many different factors, including health 
system characteristics. The complexity of all the determinants involved explains why it 
is unlikely that a ‘quick and easy’ solution will ever be found. Strategies that integrate 
medical evidence with evidence on the context of clinical practice and the patient and 
on its policy boundaries could be more successful in promoting implementation in 
clinical care. Such strategies should be designed in collaboration with guideline 
developers, clinical researchers, clinicians, the public and policymakers. They will most 
likely be multifaceted and multi-tiered and will involve education of both patients and 
physicians and include unequivocal public policy that supports the desired change. 
Identification of the gaps in our knowledge of the three evidence components and 
addressing these in research are challenges for the future. Attention to the medical, 
contextual and policy elements of interventions could be an important step towards 
more successful implementation of evidence in clinical practice, better quality of 
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In this thesis we focussed on various aspects linked to the implementation of evi-
dence in day to day clinical patient care. The conceptual framework helps us under-
stand the process of quality of care in relation to different types of evidence. We illus-
trated some of the determinants in the framework with examples from original re-
search carried out in Flanders, Belgium. However, when reflecting upon these issues, we 
feel a need to add a global perspective. 
 
We have described the empowering effect of availability of (medical) evidence. 
However, will it also empower health professionals and patients in countries with fewer 
resources? Computers and the internet, as a direct access to all this information, are not 
generally available in deprived or developing regions, where often even a reliable 
power supply is lacking. On the other hand, even if accessibility isn’t a problem, avail-
ability of relevant evidence may well be. The “10:90 gap” still exists, whereby only 10% 
of worldwide health research funds are allocated to the problems responsible for 90% of 
the world’s burden of disease, mainly in poor countries.1 An exception to this rule may 
well be HIV/AIDS, but only because it is also a problem of rich countries. Had HIV/AIDS 
not been introduced into the gay community of the Western world in the 1970s, the 
drive for AIDS-research would not have been so strong and the epidemic in Africa 
would have had an even more devastating effect. The lack of drug research on ‘non-
profitable’ infectious diseases that prevail in the South is tangibly illustrated by their 
population health statistics. Funding for research into diseases that are common in 
developing countries, like tuberculosis, malaria and other tropical infectious diseases, is 
urgently needed.2 However, both the South and the North could also benefit from 
studies of ‘cheap’ or ‘old’ treatments. The evidence that is being generated nowadays 
mainly covers new expensive medication and technologies. This could create the false 
impression that good health care equals expensive health care and thus increase the 






88      Epilogue 
 
 
The context of implementing evidence across cultures is already at our doorstep. 
Opening up to other cultural concepts of health and healthy behavior might also en-
rich our understanding of what makes efficacious interventions into effective ones. 
The issue of equity is an important challenge for the 21st century. Delivering effective 
care to those who need it when they need it enhances efficiency, but also addresses 
equity. Our responsibility for equity goes beyond our own region, and extends across 
borders into resource poor regions in the South.  
 
In this thesis we voice a plea for independent research into matters that affect pa-
tients all over the world. This includes studying diseases and treatments that lack a 
commercial interest. Research on health systems and health care delivery strategies 
focussed on the needs of the community and not on the financial profits of stake-
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A prerequisite for good quality 






A conceptual framework for research 
 
Making evidence from scientific studies available to clinical practice was expected 
to directly improve the quality of patient care. However, this expectation has not been 
met. The concept of quality of care is complex and requires a wider view. In this thesis 
we present a conceptual framework that can help us grasp the wide range of determi-
nants and processes that play a role in improving quality of care (chapter 2). When 
approaching quality improvement from a research perspective three different types of 
evidence emerge: medical, contextual and policy evidence. Making decisions in patient 
care requires sound knowledge of the disease and its management (medical evidence), 
but we must also take into account the specific context of the health care setting and 
the encounter with patients (contextual evidence) and pay attention to efficiency and 
equity (policy evidence). These three types of evidence are incorporated in an ‘evidence 
framework’ that can be used in the design and analysis of research on quality im-
provement strategies in primary care. The four research papers in this thesis explore the 
usefulness of the ‘evidence framework’ as an instrument to investigate and understand 






Medical evidence derived from clinical trials 
provides information on the efficacy of treatments 
or interventions, referring to the effect in selected 
populations, in specific settings and under 
controlled conditions. Medical evidence is the cornerstone of evidence-based medicine 
(EBM) and should therefore be reliable and of high quality. Evidence from systematic 
reviews and meta-analyses that synthesize the results of individual trials is mostly re-
garded as high level evidence to underpin recommendations for clinical practice. How-
ever, the quality and validity of a meta-analysis depends on the quality of the individual 
trials it includes. Therefore, critical appraisal of this medical evidence is an essential part 
of practising EBM. Poor trial quality and selective availability of data are important 
Summary 
 
90       Summary 
When medical evidence is 
available one would ex-
pect that transmitting 
the evidence to health 
care professionals is suf-
ficient to change practice 
and improve quality of 
care. 
issues that have been shown to jeopardize the validity of reviews. In chapter 3 we take a 
closer look at Cochrane reviews, a major source of synthesized medical evidence. We 
studied a random sample of all Cochrane reviews that included references to “unpub-
lished data only”. As these data have not been reviewed by journal editors and review-
ers, they could be an important source of bias and influence the results of reviews. Our 
study shows that searching for unpublished data in Cochrane reviews does not give a 
high yield. Moreover, 38% of the ‘unpublished’ references were (eventually) published as 
a peer-reviewed paper either within the reported search period or shortly after. Also, the 
methodological quality of the unpublished trials, in particular data from manufacturers 
or conference abstracts, was generally poor or not reported. Therefore, extensive search-
ing for unpublished trials may not be worth the effort. Rather, 
reviewers could be advised to invest in regular updating of 
their reviews. 
 
Transmission of medical evidence is a next step in 
evidence-based practice. Many different interventions aimed 
at ‘closing the gap between evidence and practice’ have been 
designed and tested, but a ‘magic bullet’ has not been found. 
In many European countries, including Belgium, small peer 
groups or local quality groups have been established as an 
instrument for quality improvement in health care. They are a core feature in national 
systems for accreditation and continuing medical education. Nevertheless, research into 
their impact on quality of patient care is scarce. In a pragmatic cluster randomized 
controlled trial we evaluated the effect on antibiotic prescribing of a self-led discussion 
of a guideline on acute rhinosinusitis in local quality circles of Belgian family physicians 
(chapter 4). By not interfering in the peer review process we aimed to approach the 
situation in ‘real life’. We found that a single intervention did not have a significant 
effect on the quantity of antibiotic prescribing (56.9% of patients received an antibiotic 
in the nine intervention groups and 58.3% in the nine control groups). Likewise, there 
was no difference in the proportion of prescribed first choice antibiotics (34.5% versus 
29.4%). This study suggests that more attention to the context of primary care practice 
and insight into the process of self-reflective learning may be needed to optimise the 
effectiveness of quality circles. 
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If medical evidence and strategies for 
transmitting the evidence are available, 
why doesn’t this result in evidence-
based practice? Why are sore throat 





Medical evidence provides information 
on ‘efficacy’, the effect of an intervention in 
a controlled setting for a carefully selected 
group of patients. However, in reality pa-
tients in primary care are a mix of people 
with various biopsychological, cultural and 
socioeconomic backgrounds, who present 
with complaints rather than a diagnosis 
and often have more than one condition. They consult doctors with specific compe-
tences (i.e. in communication), beliefs and empathy. Moreover, without the careful 
follow-up in a trial setting, they are much less adherent to the prescribed treatment. All 
these factors make up the context of clinical care and contribute to the ‘efficacy of 
interventions in real life’, i.e. the ‘effectiveness’. Information from contextual evidence 
helps us understand the gap between ‘efficacy’ and ‘effectiveness’. Information on the 
effectiveness of interventions is what clinicians really need. It answers their most impor-
tant question: ‘How will it work for my patients in my practice?’  
 
Why do physicians still prescribe antibiotics for an uncomplicated sore throat, in 
spite of the availability of a guideline that recommends refraining from antibiotics? In 
an observational study of patients consulting their doctor for an acute sore throat we 
explored this contextual evidence (chapter 5). Physicians often mention patient pressure 
for an antibiotic prescription as a reason why they do not adhere to the guideline. Our 
study questions if this is the case. An antibiotic prescription is not necessarily the pa-
tient’s main concern. Adequate analgesia may be a more important reason for seeking 
medical care. Possibly, patients who hope for an antibiotic may in fact want a treat-
ment to alleviate pain. They may mistakenly feel that antibiotics are the best treatment 
for their pain. Communicating with patients about their needs and potential miscon-
ceptions, and taking their ‘health beliefs’ into account, could help remove this obstacle 
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Information on the ‘efficacy’ of interventions 
that is based on sound medical evidence is a 
basic requirement for evidence-based practi-
ce. It needs input from evidence on contextual 
factors that determines ‘effectiveness’ of 
interventions in day to day practice. However, 
not all interventions that are efficacious and 
effective can be implemented. Health care 
budgets are limited and policymakers need to 
control costs and ensure accessibility for all its 
citizens. Can health policies, such as national 
reimbursement regulations for acid suppres-





Policymakers are mostly 
concerned with the ‘efficiency’ and 
‘equity’ of interventions. Health 
policies, including those regulating 
reimbursement of medication, can 
be powerful drivers of physicians’ 
prescribing, at least on the short 
term. These policies are usually 
inspired by cost-containment 
concerns and it is not always clear if 
this coincides with the principle of 
rational evidence-based prescribing. 
Our analysis of national prescribing 
data for acid suppressant 
medication in Belgium shows that 
indeed physicians’ prescribing 
responds to reimbursement policies (chapter 6). These policies, however, do not discri-
minate between rational and irrational use of acid suppressants and therefore cannot 
be considered as sufficient to improve quality of care. On the other hand, the clinical 
practice recommendations that were published during the observed period in a con-
sensus report on rational use of acid suppressant drugs did not have any noticeable 
impact on prescribed volumes. Our analysis also shows that some effects of reimbur-
sement policies can be unintended. This suggests that the design and evaluation of 
policies should follow a structured process and adopt evidence-based methods. Medical 
and contextual evidence should be the starting point for all policies. Stakeholders 
should refer to evidence to support their arguments. Policymakers must then consider 
efficiency and equity issues and societal and political priorities. A dialogue between 
policymakers, researchers, guideline developers, health care professionals and patients 
could be an effective way to pursue both cost-containment and quality of care. 
The four research papers in this thesis illustrate that the proposed evidence frame-
work can be useful in the analysis of determinants of quality of care. Attention to medi-
cal, contextual and policy evidence provides clues that could be instrumental in desig-
ning strategies and interventions that aim to increase the implementation of evidence 
in clinical care and thus contribute to improvement of its quality. 
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Een eerste voorwaarde voor goede 
kwaliteit van zorg is beschikbaar-




Een conceptueel kader voor onderzoek 
 
Het beschikbaar maken van de resultaten van wetenschappelijke studies (evidentie 
of ‘evidence’) in de klinische praktijk zou rechtstreeks de kwaliteit van zorg verbeteren. 
Dit is echter niet het geval. Het concept ‘kwaliteit van zorg’ is complex en vraagt om 
een bredere benadering. In deze thesis stellen wij een theoretisch kader voor dat kan 
helpen om de brede waaier van determinanten en processen in kaart te brengen die 
een rol spelen bij het verbeteren van kwaliteit van zorg (hoofdstuk 2). Wanneer we dit 
theoretische kader bekijken vanuit een onderzoeksperspectief, tekenen zich drie soor-
ten evidentie (wetenschappelijk bewijs) af: medische, contextuele en beleidsgerelateer-
de evidentie. Bij het nemen van beslissingen over patiënten dienen we te bouwen op 
degelijke kennis van de ziekte en de aanpak ervan (medische evidentie). We moeten 
echter ook de specifieke context van het arts-patiënt contact en het gezondheidszorg-
systeem (contextuele evidentie) in rekening nemen en aandacht hebben voor een 
doelmatige (efficiëntie) en billijke (equity) verdeling van de beschikbare middelen (be-
leidsgerelateerde evidentie). Deze drie soorten evidentie zijn opgenomen in een ‘evi-
dentie kader’ dat gebruikt kan worden bij het ontwikkelen en analyseren van onder-
zoek op het gebied van kwaliteitsbevordering in de eerstelijnsgezondheidszorg. De vier 
onderzoeksartikels in deze thesis exploreren het nut van dit ‘evidentie kader’ als in-
strument bij het onderzoeken van kwaliteitsverbetering in de gezondheidszorg, waarbij 






Medische evidentie verkrijgen we uit 
klinische studies en geeft ons informatie over de 
werkzaamheid (efficacy) van behandelingen of 
interventies. Hieronder verstaan we het effect bij 
geselecteerde populaties, in specifieke en gecontroleerde omstandigheden. Medische 
evidentie is de hoeksteen van evidence-based medicine (EBM) en dient daarom be-
trouwbaar en van goede kwaliteit te zijn. Evidentie op basis van systematische reviews 
en meta-analyses waarin de resultaten van individuele studies worden samengebracht, 
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94      Samenvatting 
Indien medische eviden-
tie beschikbaar is, dan 
zou het overbrengen van 
deze kennis bij professio-
nelen in de gezondheids-
zorg voldoende moeten 
zijn om hun handelen aan 
te passen en zo de kwali-
teit van hun zorg te ver-
beteren. 
wordt beschouwd als krachtig bewijs bij het onderbouwen van aanbevelingen voor de 
klinische praktijk. De kwaliteit van deze syntheses is echter afhankelijk van de kwaliteit 
van de individuele studies die erin zijn opgenomen. Het kritisch beoordelen van deze 
studies is daarom een essentieel onderdeel van het beoefenen van EBM. Een slechte 
methodologische kwaliteit en selectieve beschikbaarheid van data zijn belangrijk en 
kunnen de validiteit van de reviews in gevaar brengen. In hoofdstuk 3 nemen we de 
beschikbare Cochrane reviews, een belangrijke bron van gesynthetiseerde medische 
evidentie, onder de loep. We bestudeerden een aselecte steekproef van alle Cochrane 
reviews, die referenties naar “unpublished data only” opnemen. Omdat deze gegevens 
niet zijn beoordeeld door redacteurs van tijdschriften of andere inhoudsdeskundigen, 
zijn zij een potentiële bron van vertekening voor de resultaten van de meta-analyse. 
Onze analyse toont dat het zoeken naar ongepubliceerde studies niet veel oplevert. 
Bovendien wordt 38% van de als ongepubliceerd aangeduide referenties (uiteindelijk) 
toch gepubliceerd, ofwel binnen de gerapporteerde zoekperiode, ofwel kort daarna. De 
methodologische kwaliteit van deze ongepubliceerde studies, in het bijzonder de data 
van geneesmiddelenfabrikanten of abstracts van symposia en congressen, was over het 
algemeen slecht of niet te beoordelen. Daarom lijkt het niet de moeite om uitgebreid te 
zoeken naar meestal moeilijk te lokaliseren ongepubliceerde studies. In plaats daarvan 
kan overwogen worden om Cochrane reviewers te 
adviseren om te investeren in het regelmatig actualiseren 
van hun reviews. 
 
Het overdragen van medische evidentie is een 
volgende stap in het beoefenen van evidence-based 
practice. Met behulp van verschillende soorten 
interventies heeft men getracht om de kloof tussen 
evidentie en praktijk te overbruggen, maar een ideale 
oplossing bestaat niet. In vele Europese landen, 
waaronder België, zijn Lokale Kwaliteitsgroepen (LOK’s) 
opgestart, kleine groepen van collega’s (bijvoorbeeld 
huisartsen in een zelfde regio). Zij zijn bedoeld als instrument ter verbetering van de 
zorgkwaliteit en maken deel uit van nationale systemen voor accreditering en perma-
nente navorming in de gezondheidszorg. Onderzoek naar de impact van dergelijke 
groepen op de kwaliteit van de patiëntenzorg is echter schaars. In een pragmatische, op 
cluster niveau gerandomiseerde studie evalueerden wij het effect van een eenmalige 
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Indien de medische evidentie en strategieën 
voor het overbrengen ervan beschikbaar 
zijn, waarom resulteert dit dan niet in evi-
dence-based praktijkvoering? Waarom wor-
den patiënten met acute keelpijn nog altijd 
met antibiotica behandeld? 
door de LOK-groep zelf geleide bijeenkomst over een nieuwe praktijkrichtlijn voor de 
aanpak van acute rhinosinusitus op het voorschrijven van antibiotica (hoofdstuk 4). 
Door niet in te grijpen in het groepsproces trachtten we de toestand in de dagelijkse 
praktijk zoveel mogelijk te benaderen. We stelden vast dat een eenmalige interventie 
geen significant effect heeft op de hoeveelheid voorgeschreven antibiotica (56.9% van de 
patiënten kreeg een antibioticum in de negen interventietroepen en 58.3% in de negen 
controlegroepen). Er was evenmin een verschil tussen beide groepen in de proportie 
voorgeschreven eerste keuze antibiotica (34.5% versus 29.4%). Deze studie suggereert dat 
meer aandacht voor de context van de praktijk en meer inzicht in het proces van zelf-
reflectie en leren nodig zijn om het toepassen van EBM met behulp van lokale kwali-





Medische evidentie geeft 
informatie over de werkzaamheid 
(efficacy) van een interventie in een 
gecontroleerde setting bij een 
zorgvuldig geselecteerde groep 
patiënten. Echter, in de realiteit zijn 
patiënten in de eerstelijn een 
mengeling van personen met 
verschillende biopsychologische, culturele en sociaaleconomische achtergronden, die 
zich aanmelden met een klacht in plaats van een diagnose, en die vaak meer dan één 
aandoening hebben. Zij raadplegen artsen die elk hun eigen specifieke vaardigheden 
(bijvoorbeeld met betrekking tot communicatie), overtuigingen en empathische talen-
ten hebben. Bovendien worden patiënten in de dagelijkse praktijk minder intensief 
opgevolgd dan in een klinische studie en zijn ze ook veel minder trouw aan de voorge-
schreven behandeling. Al deze factoren vormen de context van de patiëntenzorg en 
dragen bij tot de werkzaamheid van interventies in het dagelijkse leven, namelijk de 
doeltreffendheid (effectiveness). Informatie over contextuele evidentie helpt ons om de 
kloof tussen werkzaamheid en doeltreffendheid te begrijpen. Informatie over de doel-
treffendheid is wat clinici werkelijk nodig hebben. Het geeft een antwoord op hun 
belangrijkste vraag: “Hoe werkt het bij mijn patiënten in mijn praktijk?” 
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Informatie over de werkzaamheid van interventies gebaseerd op degelijke medische 
evidentie is een eerste voorwaarde voor evidence-based praktijkvoering. Het heeft 
input nodig van contextuele factoren die de doeltreffendheid van interventies in de 
dagelijkse praktijk bepalen. Echter, niet alle interventies die werkzaam en doeltref-
fend zijn kunnen in de praktijk worden uitgevoerd. Gezondheidsbudgetten zijn be-
perkt en beleidsmakers moeten de kosten beheersen en toegankelijkheid voor alle 
burgers bewaken. Kan regelgeving, zoals de terugbetalingsregelingen voor zuurrem-
mers, bijdragen aan evidence-based voorschrijven? 
 
Waarom behandelen artsen een ongecompliceerde acute keelpijn nog altijd met 
antibiotica, terwijl er een richtlijn beschikbaar is die aanbeveelt om er geen voor te 
schrijven? In een observationeel onderzoek bij patiënten die hun huisarts raadpleegden 
voor een acute keelpijn, exploreerden we de contextuele evidentie (hoofdstuk 5). Artsen 
vermelden vaak dat zij onder druk van hun patiënten antibiotica voorschrijven. Ons 
onderzoek stelt dit argument in vraag. Een voorschrift voor een antibioticum was niet 
noodzakelijkerwijs de belangrijkste zorg van de patiënt. Goede pijnstilling zou wel eens 
een belangrijker reden kunnen zijn om hulp te zoeken. Het is mogelijk dat patiënten 
die een antibioticum verwachten eigenlijk iets tegen de pijn willen en onterecht den-
ken dat een antibioticum het beste medicijn hiervoor is. Door met patiënten te praten 
over hun wensen en mogelijke misvattingen en door aandacht te geven aan hun   
ideeën over hun eigen gezondheid, zouden deze obstakels uit de weg geruimd kunnen 
worden en de weg kunnen open staan naar rationeler en meer evidence-based voor-







Beleidsmakers zijn vooral geïnteresseerd in de doelmatigheid (efficiency) en de bil-
lijkheid (equity) van interventies. Beleidsmaatregelen, waaronder terugbetalingsregelin-
gen voor geneesmiddelen, kunnen krachtige drijfveren zijn van voorschrijfgedrag van 
artsen zeker op korte termijn. Dergelijke maatregelen zijn meestal geïnspireerd door 
kostenbeheersing en het is niet altijd duidelijk of dit principe overeenkomt met het 
principe van rationeel evidence-based voorschrijven. Onze analyse van de Belgische 
federale databank (Farmanet) toont dat de voorgeschreven volumes van zuurremmers 
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inderdaad reageren op de verschillende terugbetalingsregelingen (hoofdstuk 6). Echter, 
deze maatregelen maken geen onderscheid tussen rationeel en irrationeel gebruik van 
zuurremmers en kunnen dus niet beschouwd worden als afdoende maatregel ter ver-
betering van de kwaliteit. Anderzijds zien we geen impact op de voorgeschreven volu-
mes van het in dezelfde periode verspreide consensusrapport van het RIZIV over het 
doelmatige gebruik van zuurremmers. Onze analyse toont ook dat terugbetalingsrege-
lingen soms een onbedoeld effect hebben. Dit alles suggereert dat het ontwerpen en 
evalueren van beleidsmaatregelen een gestructureerde procedure en evidence-based 
methode zouden moeten volgen. Medische en contextuele evidentie dienen het uit-
gangspunt te zijn van alle beleid en de referentie voor argumenten van alle betrokken 
partijen. Beleidsmakers dienen vervolgens de doelmatigheid en billijkheid te beoorde-
len en dit alles te plaatsen in de maatschappelijke en politieke prioriteiten. Een dialoog 
tussen beleidsmakers, onderzoekers, richtlijnontwikkelaars, gezondheidsprofessionals 
en patiënten zou een effectieve manier kunnen zijn om zowel kostenbeheersing als 
kwaliteit van zorg na te streven. 
 
De vier onderzoeksartikels in dit proefschrift illustreren dat het voorgestelde ‘evi-
dentie kader’ nuttig kan zijn bij het onderzoeken van de determinanten van kwaliteit 
van zorg. Aandacht voor medische, contextuele en beleidsgerelateerde evidentie levert 
belangrijke informatie. Deze kan bruikbaar zijn bij het onderzoeken en ontwikkelen 
van strategieën en interventies, die het toepassen van de resultaten van wetenschappe-
lijk onderzoek in de praktijk kunnen bevorderen. Op deze wijze kan een bijdrage gele-
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Les preuves médicales comme pré 





Un cadre conceptuel pour une recherche 
 
La mise à disposition, au niveau de la pratique clinique, des résultats des études 
scientifiques ( les « faits » ou preuves) améliorerait directement la qualité des soins. Tel 
n’est cependant pas le cas. Le concept « qualité des soins » est complexe et exige un 
abord beaucoup plus vaste. Dans cette thèse, nous développons un cadre théorique 
nous permettant d’inclure le grand éventail des déterminants et processus impliqués 
dans l’amélioration de la qualité des soins (chapitre 2). Lorsque nous examinons ce 
cadre théorique dans une perspective de recherche, trois types de « preuves » émergent : 
médicales, contextuelles et politiques (‘policy evidence’). Une prise de décision en ma-
tière de soins aux patients doit se baser sur une connaissance solide de la pathologie et 
de sa prise en charge (preuves médicales). Nous devons toutefois tenir compte du 
contexte spécifique des soins de santé et de la relation médecin-patient (preuves contex-
tuelles) en restant attentifs à une répartition efficiente et équitable des moyens disponi-
bles (preuves au niveau d’une politique). Ces trois types de preuves sont incorporés dans 
un « cadre de preuves » que nous pourrons utiliser pour élaborer et analyser des recher-
ches dans le domaine des stratégies pour la promotion de la qualité en première ligne 
de soins. Les quatre publications de recherche reprises dans cette thèse explorent 
l’utilité de ce « cadre de preuves » en tant qu’instrument permettant de situer et de 
comprendre les recherches nécessaires pour améliorer la qualité des soins en ayant 
recours aux résultats des études scientifiques. 
 
 
Les preuves médicales 
 
Les preuves médicales sont issues des 
études cliniques et nous apportent des 
informations sur l’efficacité (‘efficacy’) de 
traitements ou d’interventions, dans certaines populations sélectionnées et dans des 
circonstances spécifiques et contrôlées. Les preuves médicales constituent la pierre 
d’angle de l’evidence-based medicine (EBM) et doivent, à ce titre, être fiables et de 
bonne qualité. Les preuves issues de synthèses méthodiques et de méta-analyses som-
mant les résultats d’études individuelles sont considérées comme une preuve solide lors 
Résumé 
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Quand des preuves médicales 
sont disponibles, les porter à 
la connaissance des profes-
sionnels des soins de santé 
devrait suffire pour leur 
permettre d’adapter leur 
pratique et améliorer la 
qualité des soins. 
de l’élaboration de recommandations pour la pratique clinique. La qualité de ces syn-
thèses est cependant dépendante de la qualité individuelle des différentes études 
qu’elles incluent. Une évaluation critique de ces études constitue une des tâches essen-
tielles de la pratique de l’EBM. Une piètre qualité méthodologique comme une disponi-
bilité sélective des données sont des éléments importants qui peuvent mettre en péril la 
validité des synthèses. Dans le chapitre 3, nous analysons de plus près des synthèses de 
la Cochrane, source importante de « preuves médicales » synthétisées. Nous évaluons 
un échantillon aléatoire de l’ensemble de ces synthèses Cochrane qui incluent des réfé-
rences à des ‘unpublished data only’. Ces données ne sont pas évaluées par les rédac-
teurs de revues ni par d’autres experts au niveau contenu, et, pour ce motif, elles intro-
duisent un biais potentiel pour l’ensemble des résultats de la méta-analyse. Notre pro-
pre analyse montre que la recherche des études non publiées apporte peu d’éléments. 
En outre, 38% des références indiquées comme n’ayant pas été publiées sont (finale-
ment) quand même publiées soit pendant la période de recherche mentionnée, soit 
peu de temps après. La qualité méthodologique de ces études non publiées, en particu-
lier les données en provenance des fabricants de médicaments ou les résumés de sym-
posium ou de congrès, est, en général, mauvaise ou non mentionnée. Il semble donc 
peu utile de se fatiguer à chercher des études non 
publiées par ailleurs difficiles à localiser. Les reviewers 
Cochrane auraient tout intérêt à plutôt investir ce 
temps dans l’actualisation régulière de leurs synthèses. 
 
 
La transmission des preuves médicales est l’étape 
suivante dans une démarche evidence-based medicine. 
Différents types d’intervention ont été proposés pour 
combler le fossé entre « les preuves » et la pratique ; une 
solution idéale n’existe pas. Dans de nombreux pays 
européens, dont la Belgique, de petits groupes de confrères (par exemple de médecins 
généralistes d’une même région) se sont constitués (les Groupes Locaux d’Evaluation 
Médicale ou GLEMs). Leur but est de servir d’outil pour l’amélioration de la qualité des 
soins ; ils font partie d’un processus d’accréditation de formation continue permanente 
dans le cadre des soins de santé. Les évaluations de l’impact de la mise en place de tels 
groupes en termes de qualité pour les soins dispensés au patient sont cependant rares. 
Dans une étude pragmatique avec randomisation par grappes, nous avons évalué 
l’efficacité de l’organisation, par le GLEM-même, d’une réunion dont le thème était un 
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Les preuves médicales et les stratégies 
pour leur implantation étant disponibles, 
pourquoi pas de pratique basée sur les 
preuves? Pourquoi les patients présentant 
un mal de gorge aigu sont-ils toujours 
traités avec des antibiotiques ? 
nouveau guide de pratique pour la prise en charge de la rhinosinusite aiguë. 
L’évaluation portait sur la prescription d’antibiotiques (chapitre 4). En ne nous impli-
quant pas dans le processus de « revue par les pairs » (‘peer review’), nous pensions 
mieux approcher la réalité de la pratique quotidienne. Nous avons observé l’absence 
d’effet d’une intervention unique sur la quantité d’antibiotiques prescrits (56.9% des 
patients ont reçu un antibiotique dans les neuf groupes avec intervention et 58.3% dans 
les neuf groupes contrôle). Il n’y a également pas de différence observée entre les deux 
groupes dans la proportion de prescription de l’antibiotique recommandé comme 
premier choix (34.5% versus 29.4%). Cette étude suggère qu’il faut réserver plus 
d’attention au contexte de la pratique et mieux comprendre le processus 
d’autoévaluation critique pour pouvoir optimaliser la mise en pratique de l’EBM grâce à 





Les preuves médicales livrent des 
informations concernant l’efficacité 
(‘efficacy’) d’une intervention dans un 
contexte contrôlé et sur un groupe de 
patients soigneusement sélectionnés. 
Dans la réalité, la patientèle en première 
ligne de soins est cependant un 
patchwork de personnes avec leur propre 
contexte biopsychologique, culturel et socio-économique, qui se présentent avec une 
plainte plutôt qu’avec un diagnostic et souvent aussi avec plus d’une affection. Ils 
consultent des médecins qui ont, eux aussi, leurs propres aptitudes (par exemple en 
matière de communication), convictions et talents d’empathie. En outre, en pratique 
quotidienne, les patients sont suivis moins intensément que dans le cadre d’une étude 
clinique et ils sont moins observants pour le traitement qui leur est prescrit. Tous ces 
facteurs constituent le contexte des soins aux patients et interviennent au niveau de 
l’efficacité des interventions dans la vie de tous les jours, appelée efficacité pratique, 
clinique ou utilité (‘effectiveness’). Une information concernant les preuves contextuel-
les nous aide à comprendre le hiatus entre efficacité et utilité. Cette information ayant 
trait à l’utilité représente une réponse au besoin réel des cliniciens. Elle apporte en effet 
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Une information concernant l’efficacité des interventions, basée sur des preuves 
médicales solides est la condition première pour une pratique basée sur des preu-
ves. Les facteurs contextuels qui déterminent l’efficacité clinique (utilité) des 
interventions dans la pratique quotidienne doivent y être ajoutés. Toutes les in-
terventions efficaces et utiles ne peuvent cependant être réalisées dans la prati-
que. Les budgets pour la santé sont limités et les décideurs doivent maîtriser les 
coûts et préserver une accessibilité pour tout citoyen. La réglementation, par 
exemple celle concernant le remboursement des inhibiteurs de la sécrétion acide 
gastrique, peut-elle contribuer à une prescription basée sur les preuves ? 
une réponse à leur question la plus importante: “Quel effet pour mes patients, dans ma 
pratique ?”.  
 
Pourquoi les médecins traitent-ils encore toujours un mal de gorge non compliqué 
avec des antibiotiques alors qu’ils disposent d’un guide de pratique leur recommandant 
de n’en point prescrire ? Dans une étude d’observation incluant des patients consultant 
leur médecin généraliste pour un mal de gorge aigu, nous avons étudié les preuves 
contextuelles (chapitre 5). Les médecins racontent souvent qu’ils prescrivent des antibio-
tiques sous la pression de leurs patients. Notre enquête met cet argument en doute. La 
prescription d’un antibiotique n’était pas nécessairement le souci principal du patient, 
plus préoccupé, dans sa recherche d’aide, d’obtenir un soulagement correct de sa dou-
leur. Il est possible que les patients qui désirent un antibiotique attendent en fait un 
traitement de la douleur et qu’ils estiment que l’antibiotique est le meilleur médica-
ment pour atteindre ce but. En dialoguant avec les patients à propos de leurs souhaits 
et de conceptions peut-être erronées, en réservant l’attention nécessaire à leurs idées 
concernant leur santé, ces obstacles pourraient largement sauter et la voie s’ouvrir vers 
une prescription d’antibiotiques plus rationnelle et basée sur les preuves.  
 
 
Preuves au niveau d’une politique 
 
 
Les décideurs sont surtout intéressés par l’efficience et l’équité des interventions. Les 
règlements, dont la réglementation concernant le remboursement des médicaments, 
peuvent modifier fortement le comportement de prescription des médecins, certaine-
ment à court terme. De telles mesures sont généralement inspirées par un contrôle des 
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coûts et il n’est pas toujours évident que ce principe corresponde à une prescription 
rationnelle basée sur les preuves. Notre analyse d’une base de données fédérale belge 
(Pharmanet) montre que les volumes d’inhibiteurs de la sécrétion acide gastrique sont 
effectivement influencés par les différentes réglementations de remboursement (chapi-
tre 6). Ces mesures ne font cependant pas la distinction entre un usage rationnel et une 
utilisation irrationnelle de ces médicaments et ne peuvent donc être considérées 
comme des mesures visant avec conviction une amélioration de la qualité. D’autre part, 
nous n’observons aucun impact sur les volumes prescrits du rapport de consensus de 
l’INAMI sur ce sujet des inhibiteurs de la sécrétion acide gastrique, rapport diffusé du-
rant la même période. Notre analyse montre aussi que les réglementations concernant 
le remboursement ont parfois un effet non désiré. Tout ceci suggère que la conception 
et l’évaluation des réglementations devraient suivre un processus structuré et une mé-
thode basée sur des preuves. Les preuves médicales et contextuelles doivent être le 
point de départ de toute politique et servir de référence dans les arguments de toutes 
les parties concernées. Les décideurs doivent ensuite évaluer l’efficience et l’équité ainsi 
que mettre tout ceci en perspective des priorités sociales et politiques. Un dialogue 
entre les décideurs, les chercheurs, les personnes qui élaborent des guides de pratique, 
les professionnels de la santé et les patients serait une manière efficace de viser à la fois 
un contrôle des coûts et une qualité des soins. 
Les quatre articles de recherche figurant dans cette thèse illustrent que le « cadre de 
preuves » proposé peut être utile dans la recherche de déterminants de qualité de soins. 
Etre attentif aux preuves médicales, contextuelles et d’une politique, livre des informa-
tions utilisables pour investiguer et élaborer des stratégies et des interventions pouvant 
favoriser l’implantation de résultats de recherches scientifiques dans la pratique et 

















The implementation of evidence in clinical care.  Ex-
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Een dikke boom  
begint als  
een teer twijgje.  
 
Een bergbeklimming  
begint  
met een stapje. 
 
Lao-Tse, Chinese filosoof  





Stap voor stap is dit proefschrift tot stand gekomen en onderweg zijn er velen met 
mij meegestapt. Met veel steun en vriendschap is dit boekje er gekomen en daar ben ik 
jullie heel dankbaar voor. Dit hoofdstuk is speciaal voor jullie. 
 
 
Een eerste woord van dank is voor de patiënten en artsen, die hebben meegewerkt 
aan de onderzoeksprojecten van deze thesis. Van hen heb ik veel geleerd. Hun bijdrage 
is onmisbaar in ons streven naar een betere kwaliteit van de patiëntenzorg.  
 
 
Zonder compleet te zijn, wil ik ook een aantal mensen persoonlijk noemen. 
 
Thierry, mijn promotor, met je kalme en relativerende feedback heb je me steeds 
weer met mijn benen terug op de grond weten te zetten. Dat was soms hard nodig, 
want er was zoveel interessant. De laatste maanden was je niet alleen een geweldige 
gesprekspartner die mij hielp om de inleiding en discussie te verdiepen, maar vooral 
ook een fijne coach. 
 
 
Floor, mijn co-promotor, je vroeg me ooit of het geen bezwaar was dat je zo ver 
weg in Groningen zat. Die afstand heb ik nooit gevoeld. Op momenten dat ik twijfelde 
of je advies nodig had, was je er en nam je de tijd. Met jouw nuchtere en deskundige 
reflecties kon ik daarna weer voort. 
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Jan, mijn vakgroepvoorzitter en inspirator van dit proefschrift, je hebt me de kans 
gegeven om aan een doctoraat te werken en ons artikel in ‘the Lancet’ was daarvoor 
een mooi uitgangspunt. Op de achtergrond dacht je altijd mee en soms waren enkele 




Mijn collega’s van de Vakgroep Huisartsgeneeskunde en Eerstelijnsgezondheidszorg, 
jullie vormen een warm nest waarin ik met veel plezier werk. Op de gang, in de keu-
ken of in het kopieerlokaal kunnen we bij elkaar verzuchten dat er weer eens teveel 
werk is, maar ontstaan ook ideeën voor nieuwe projecten. We sparen elkaar niet als we 
elkaars werk beoordelen of samen artikels schrijven, maar steunen elkaar door dik en 
dun. Een beter team kan ik niet wensen. Myriam, An en Sara, jullie gingen mij voor en 
gaven mij moed. Dat hoop ik ook te geven aan degenen die na mij komen. Ons secre-
tariaat, Thérèse, Emilienne, Claudine, Michèle, Anja, Nico en Karine, op jullie kon ik 
altijd rekenen. Thérèse, ik ben heel blij dat ik de organisatie van mijn doctoraatsviering 
nog aan jou mag toevertrouwen. Bedankt. 
 
 
Marc, als hoofdredacteur van Minerva was het niet altijd evident om mij te sparen. 
Maar met jouw steun is het gelukt om naast een thesis nog maandelijks een nummer 
van Minerva af te leveren. Daarbij ben ik in het bijzonder ook bijgestaan door mijn 
collega-eindredacteur Pierre, die in de laatste hectische maanden spontaan een veilig 
vangnet was. Ik dank ook al mijn collega’s van de Minerva redactie met wie ik door de 
jaren heen evidence-based medicine heb leren ontdekken: Anne, Barbara, Etienne, Gert, 
Marc, Michel, Paul en Tom. De discussies op de redactievergaderingen zijn een onuit-
puttelijke bron van inspiratie en een uitdaging om steeds dieper te graven in de grond 
van wetenschappelijk onderzoek.  
 
 
Mijn collega’s bij Project Farmaka, samen hebben we al heel wat literatuur verslon-
den en herkauwd. We mogen fier zijn op waar we nu staan. Fier ben ik ook dat jullie 
door onze samenwerking in de sinusitisstudie een plaats hebben in mijn doctoraat. 
Bedankt, Dominique, Hilde, Isabelle en Koenraad en de artsenbezoekers van de sinusi-
tisstudie An en Kristien.  
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De andere collega’s die mij bijstonden in de onderzoeksprojecten van deze thesis, 
Janique, Marleen, Sibyl, Siegfried en Tom, dank ik voor de fijne samenwerking. 
 
 
Ik dank alle co-auteurs van de publicaties waaraan ik heb gewerkt. Schrijven is een 
proces van lange adem dat alleen in een team tot een goed einde gebracht kan wor-
den. In het bijzonder dank ik Samuel en Wim voor hun ondersteuning bij de statisti-
sche kronkels op ons pad. 
 
 
Heel dankbaar ben ik de vrienden die mij hebben geholpen bij het maken van dit 
boek. Kris, bij jou kan ik altijd terecht voor van alles. Met je creativiteit en inzicht maak-
te je van mijn ‘saaie thesis’ een prachtig boekje.  
Dank aan Pierre voor het vertalen van de samenvatting naar het Frans. En, zoals ik 
je ken, je hielp me zelfs om de Nederlandse tekst te verbeteren.  
I am very grateful to my ‘uncle Sam’ from Taiwan, who provided the Chinese sum-
mary. Thanks to his efforts my work will be accessible to colleagues and friends in the 
Far East.  
My dear friend Richard, my favorite editor from Denver, Colorado, proof read my 
writing and added an idiomatic touch. I definitely owe you a bike ride! 
Ik ben heel trots op mijn zus, Louise, die zoveel prachtige tekeningen maakte, dat 
het moeilijk was om er een te kiezen voor de kaft van dit boek.  
 
 
Mijn familie, schoonfamilie en vrienden dank ik voor hun aanmoedigingen en ver-
trouwen dat het ‘toch ooit af zou geraken’. In deze laatste fase van mijn thesis heb ik 
peter’s kritische vragen gemist. Hij leerde mij altijd relativeren en daagde mij steeds uit 
om mijn argumenten aan te scherpen. 
Aan mijn ouders heb ik dit proefschrift opgedragen. Zij leerden mij dat grenzen er 
zijn om verkend en verlegd te worden, dat uitdagingen er zijn om aan te pakken en 
dat liefde en vertrouwen de beste basis zijn voor groei. Jullie hebben mij vaak zien 
vertrekken naar verre onbekende oorden, misschien wel met een klein hartje, maar dat 
was een prachtig cadeau. Wetenschappelijk werk zie ik als een andere manier om de 
grenzen om mij heen te verkennen. Daarmee legden jullie de basis voor dit doctoraat. 
 
112      Dankwoord 
Stefan, al 15 jaar zijn we een hecht team. Ook dit project hebben we samen tot een 
goed einde gebracht. Vooral de laatste maanden waren hectisch en moest er vaak  
geïmproviseerd worden, maar we hadden al voor hetere vuren gestaan. Je stond altijd 
achter, naast en voor mij en was een rustpunt in woelige tijden. Klaar voor een volgend 
project? 
 
Sofie en Emma, jullie krijgen nu (eindelijk) het laatste woord. Sofie, jouw tekening 
sluit dit dankwoord af. Emma, met jouw heelal heb je al heel wat grenzen verlegd. 
Jullie kunnen gerust zijn, want 
jullie zien opgroeien en samen de 
wereld verkennen, is nóg veel 
leuker dan een doctoraat maken. 




































Mieke (Marie Louise) van Driel was born November 28 1959 in Rotterdam, the 
Netherlands. In 1966 the family moved to Taiwan, where she attended the Kaohsiung 
Dominican School. It was there that she learned to read and write from Dominican 
Sisters from the Philippines in a multi-ethnic and multicultural environment. When the 
family returned to the Netherlands in 1969 her great-aunt Toos, headmistress of a pri-
mary school in Rotterdam, helped her to catch up with her mother tongue. 
She attended ‘Het Nieuwe Lyceum’ in Bilthoven, where she obtained her diploma 
Gymnasium-B in 1977. When given a chance to enter medical school at the University 
of Utrecht, she took a rain check on plans to explore other countries and cultures. Be-
tween internships she traveled to the United States, where she spent several months at 
various health care facilities and at the J.F. Kennedy Center for Child Development in 
Denver, Colorado. She continued her internships in Dutch hospitals and graduated as 
an MD in November 1984.  
 
 
At the time of her graduation, future career perspectives for young doctors looked 
grim. Although there was enough work in patient care, opportunities for an acknow-
ledged training position as a specialist were scarce. As a result, many freshly graduated 
MDs ended up working as assistant doctors in hospitals without the prospect of spe-
cialization (the “AGNIO’s”, Assistent Geneeskundige Niet In Opleiding). Mieke was one 
of the founders and a member of the executive committee of the LBB (Landelijke 
Belangenvereniging voor Basisartsen), a national doctors’ association that strived to 
bring this issue to the attention of politicians. Her thesis, a survey of recently graduated 
physicians from Utrecht University, provided the evidence-base for the LBB’s advocacy 
and was awarded a prize for “encouraging research” by the Board of Governors of the 
University. At the same time she was involved in various activities at the Women’s 
Health Center in Utrecht, including information services, a library, research (use of the 
pessarium occlusivum as a contraceptive method) and advocacy (sexual assault of fe-
male clients by health care professionals). As an MD she worked at the Red Cross Blood 
Bank and at the CBO (Institute for quality of care) in Utrecht. 
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In 1987 she took a backpack and flew to Taiwan, where during six months she im-
mersed herself in the hospitable culture that had shaped her childhood. In a China 
Studies Seminar she learned the basics of the Chinese language and made friends from 
all continents. The following six months she explored the cultures of South-East Asia.  
 
 
Convinced of her choice for primary care, she started vocational training in general 
practice at Utrecht University. Paul and Eline Willemsen in Zaltbommel warmly intro-
duced her to a challenging and rewarding profession. She celebrated her registration as 
a General Practitioner in 1989 with a trip on the Trans-Siberian railway. Together with 




Back in the Netherlands she worked as a GP in various practices and prepared for 
enrollment at the Institute of Tropical Medicine in Antwerp, Belgium. With a diploma 
in tropical medicine she travelled to China in 1990 on an assignment for Médecins Sans 
Frontières-Belgium. Her primary health care project was located in Wulan, a rural 
county on the Qinghai-Tibet Plateau, 1500 km west of Beijing. In 1991 she moved to 
Lhasa, Tibet, where she and a French nurse started a new project of primary care assis-
tance and tuberculosis control in two rural counties, Linzhou and Nimu. In 1992 Stefan 
Thielemans joined the team to establish and coordinate the urgently needed infrastruc-
ture, providing the health care staff with proper clinics and the population with clean 
water. They also initiated a program of physiotherapy and rehabilitation in villages 
with children and adults disabled by Kashin-Beck’s disease (“Big bone disease”). She 
exchanged the wild beauty of the Himalayan Mountains in 1993 for the lush paddy 
fields of Cambodia, a country recovering from the harsh Khmer Rouge regime and 
guided by UN blue helmets towards free elections. She coordinated an MSF team work-
ing in the provincial and district hospitals of Pursat and learned about malaria control, 
hospital management and the terror of land mines. In June 1994 she took up an assign-
ment in Rwanda, where a few months earlier the genocide had taken place, leaving the 
country empty and ravaged. She led a team of motivated health professionals towards 
rehabilitation of primary care services and care for refugees on their way home. She 
was medical coordinator for the joint missions of MSF Belgium, Holland and France. 
After this experience in emergency relief she enrolled at the London School of Hygiene 
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and Tropical Medicine. The course and the inspiring multicultural group of students 
fostered her interest in epidemiology and public health. She obtained a Master’s degree 




She then settled in Belgium. For the Dutch National Institute of Infectious Disease 
Control (LCI) she developed a practice guideline on the management of Lyme disease. 
At the Department of General Practice of the Free University of Brussels she participated 
in a breast cancer screening project. In 1998 she was recruited as an editor for “Mi-
nerva”, a new independent Belgian journal for evidence-based medicine in primary 
care. She is currently responsible for the Flemish edition and has produced a glossary of 
statistical and epidemiological terms (in Dutch and French) which is also used in teach-
ing. At Project Farmaka in Ghent she is involved in developing literature reviews, e.g. for 
the consensus conferences of the Belgian National Institute for Sickness and Invalidity 
Insurance (RIZIV/INAMI) and participates in the project of academic detailing in pri-
mary health care. She joined the Department of General Practice and Primary Health 
Care of Ghent University in 1999 to organize training in evidence-based medicine and 
to initiate research in the domain. Since 2001 she has carried out the research projects 
that have led to this PhD thesis. 
 
 









































Uitsluitend door toeval geselecteerd.  
 
Betrouwbaarheidsinterval (BI) [Confidence Interval (CI)] 
In een klinisch onderzoek kan men zelden de gehele populatie onderzoeken. 
Meestal moet men zich beperken tot een kleinere groep binnen de gehele populatie 
(een steekproef). Het betrouwbaarheidsinterval geeft het gebied van waarden aan, 
waarbinnen de werkelijke waarde in de populatie met een zekere graad van waar-
schijnlijkheid ligt. Meestal wordt een waarschijnlijkheid van 95% gebruikt. Dit bete-
kent dat wanneer we het onderzoek 100 maal in dezelfde populatie met verschil-
lende steekproeven zouden herhalen 95 van de herhalingen een resultaat geven dat 
binnen het interval ligt. Dit noemen we een 95% betrouwbaarheidsinterval (95% BI). 
Het betrouwbaarheidsinterval zegt iets over de nauwkeurigheid van de in het on-
derzoek gevonden schattingen van het effect. Het betrouwbaarheidsinterval hangt 
af van de variabiliteit (in de vorm van de standaard deviatie) en de grootte van de 
steekproef (het aantal personen in de onderzoekspopulatie). Hoe groter de steek-
proef, des te smaller is het betrouwbaarheidsinterval en des te nauwkeuriger is de 
schatting van het effect. 
 
Bias  
Wanneer er sprake is van bias of vertekening wijken de resultaten van een onder-
zoek of de interpretatie ervan af van de werkelijkheid door een systematische fout. 
Vertekening kan optreden als gevolg van een fout in elk van de stappen van een 
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onderzoek; zoals bij de opzet van de studie, het verzamelen van de gegevens, het 
analyseren, het interpreteren van de resultaten en het publiceren.  
Publicatiebias (publication bias) is een vorm van vertekening die belangrijk is bij 
meta-analyses. Indien publicatie van studies afhangt van de grootte, de richting of 
de statistische significantie van de resultaten, is er sprake van publicatiebias. Het 
samenbrengen van eenzijdige onderzoeksresultaten (bijvoorbeeld alleen in het 
voordeel van een nieuw geneesmiddel), kan in een meta-analyse een vertekend 
beeld geven (een overschatting) van het werkelijke effect van de interventie. 
 
Blindering [blinding] 
In experimenteel onderzoek spreekt men van blindering wanneer patiënten, artsen 
en personen die het effect beoordelen niet op de hoogte zijn van de toegewezen 
behandeling. Deze procedure wordt toegepast bij interventiestudies (RCT’s) om te 
voorkomen dat de uitkomst van het onderzoek wordt beïnvloed. 
In een enkelblinde opzet (single blind) is slechts een van de betrokken partijen, bij-
voorbeeld de onderzoeker/behandelend arts of de patiënt niet op de hoogte van de 
toegediende behandeling. 
In een dubbelblind onderzoek zijn noch de behandelend arts, noch de deelnemers 
aan het onderzoek op de hoogte van de toegewezen behandeling.  
Een blinde uitkomstevaluatie houdt in dat het klasseren of benoemen van de uit-
komsten wordt uitgevoerd door personen, die niet op de hoogte zijn van de groep 
waarin de patiënten zijn ingedeeld. 
 
Clinical Trial [CT] 
Een klinische studie (interventiestudie) onderzoekt de werkzaamheid en veiligheid 
van een interventie of een geneesmiddel. Bij klinische studies over geneesmiddelen 
onderscheidt men vier fases.  
In fase I wordt de molecule voor het eerst geïntroduceerd bij mensen nadat het op 
dieren is getest. In deze fase onderzoekt men vooral de veiligheid van het nieuwe 
geneesmiddel, o.a. hoeveel toegediend kan worden zonder ernstige ongewenste ef-
fecten te veroorzaken. Tevens bestudeert men de metabolisatie. Men gebruikt hier-
voor gezonde vrijwilligers. In deze fase is het onderzoek meestal niet gerandomi-
seerd en is er geen controlegroep. 
In fase II onderzoekt men vooral de werkzaamheid van het nieuwe product bij ver-
schillende doseringen en toedieningsmodaliteiten. De onderzoeksgroepen bestaan 
meestal uit een 20-tal personen met een bepaalde aandoening. Ook in deze fase 
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worden de proefpersonen vaak niet aselect verdeeld over een interventie- en een 
controlegroep. 
In fase III vindt een uitgebreide klinische studie plaats. Hierbij zijn grotere groepen 
proefpersonen betrokken en worden de werkzaamheid en veiligheid verder onder-
zocht. Dit gebeurt meestal in de vorm van een RCT. Proefpersonen worden aselect 
ingedeeld in verschillende onderzoeksgroepen. Men vergelijkt het effect met een 
placebo of standaardbehandeling. 
Fase IV studies worden pas uitgevoerd als het geneesmiddel officieel geregistreerd 
en op de markt gebracht is. In deze fase wordt bijvoorbeeld het optreden van on-
gewenste effecten en het effect van langdurig gebruik opgevolgd. Fase IV studies 
worden ook wel ‘postmarketing surveillance studies’ genoemd. Dit zijn geen RCT’s. 
 
Een controlled clinical trial is een klinische studie waarbij men een of meer inter-
ventiegroepen vergelijkt met een of meer controlegroepen, die de interventie niet 
krijgen. 
 
Een randomised controlled trial (RCT) is een controlled clinical trial, waarbij de 
onderzoekspopulatie op aselecte wijze is verdeeld in een interventiegroep en een 
controlegroep. In een placebogecontroleerde RCT krijgt de controlegroep een pla-






De Cochrane Collaboration is een internationale organisatie, die zich tot doel stelt 
om ondersteuning te bieden bij het nemen van geïnformeerde beslissingen over 
gezondheidszorg. Zij doet dit door systematische reviews en meta-analyses te publi-
ceren over de effecten van gezondheidsinterventies. 
 
Cochrane Library 
De Cochrane Library is een initiatief van de Cochrane Collaboration en bestaat uit 
een aantal databanken. De Cochrane Database of Systematic Reviews (CDSR) bevat 
alle Cochrane Reviews.  
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Cochrane Review 
Dit is een systematische review (of meta-analyse) die is uitgevoerd in het kader van 
de Cochrane Collaboration. Deze reviews volgen een vast onderzoeksprotocol dat is 
opgesteld door de Cochrane Collaboration. In deze reviews zijn data uit de afzon-
derlijke studies vaak statistisch gepoold tot een meta-analyse.  
 
Concealment of allocation  
Bij een RCT worden de personen in de onderzoekspopulatie aselect ingedeeld in in-
terventiegroep(en) en controlegroep(en). ‘Concealment of allocation’ refereert aan 
het geheim houden of blinderen van deze toewijzing van patiënten aan de verschil-
lende onderzoeksgroepen. Degene die de patiënten indeelt weet niet in welke groep 
ze terechtkomen. Op deze wijze voorkomt men dat er een selectie optreedt van pa-
tiënten in de onderzoeksgroepen (allocation bias).  
 
Conflict of interest [belangenvermenging] 
Hierbij vermelden auteurs van een publicatie hun persoonlijke financiële of andere 




Een overeenkomst van meningen van personen over eenzelfde onderwerp. 
 
DDD [Defined Daily Dose] 
DDD is de gemiddelde dagelijkse dosis van een geneesmiddel voor de voornaamste 
indicatie bij volwassenen. 
 
Doelmatigheid [efficiency] 
De doelmatigheid of efficiëntie (efficiency) van een behandeling of interventie ver-
wijst naar het bereikte effect in relatie tot de benodigde middelen (geld, tijd, perso-
nen). Dit wordt ook wel uitgedrukt als de kosten per eenheid van het gewenste ef-
fect. Een efficiënte behandeling of interventie geeft het gewenste effect tegen een 
minimum aan kosten.  
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Doeltreffendheid [effectiveness]  
De doeltreffendheid (effectiveness) van een geneesmiddel of interventie verwijst 
naar de mate waarin het doel van de behandeling wordt bereikt in de alledaagse 




Evidence-Based Medicine is het oordeelkundig gebruik maken van systematisch ver-
zamelde resultaten van wetenschappelijk onderzoek bij het nemen van beslissingen 
voor individuele patiënten. EBM in de praktijk toepassen impliceert het integreren 
van klinische expertise met beschikbaar wetenschappelijk bewijs, waarbij de voor-
keur en opvattingen van de patiënt een belangrijke rol spelen (Sackett et al). 
 
Eindpunt [outcome] 
Datgene wat men meet om het resultaat van een interventie te meten wordt eind-
punt of uitkomst genoemd. Naar gelang de aard van het gekozen eindpunt kan 
men een onderscheid maken in harde eindpunten zoals dood of aangetoonde 
morbiditeit en intermediaire of surrogaat eindpunten. De intermediaire eindpun-
ten zijn afgeleide parameters die meestal alleen indirect samenhangen met harde 
eindpunten. Serumcholesterolwaarden bijvoorbeeld, kunnen beschouwd worden 
als intermediaire eindpunten in onderzoek naar het effect van medicatie, waarbij 
cardiovasculair overlijden een harde uitkomst is. Wanneer er geen directe relatie is 
aangetoond tussen het intermediaire eindpunt en relevante harde eindpunten, is de 
waarde van studies die slechts intermediaire eindpunten weergeven zeer beperkt. 
 
Equity 
Deze term uit de (gezondheids)economie impliceert dat gezondheidszorg beschik-
baar is voor iedereen (billijkheid). Dat wil zeggen dat er geen verschillen bestaan in 




In tegenstelling tot observationeel onderzoek grijpt men bij een experimentele on-
derzoeksopzet in de ‘natuurlijke gang van zaken’ in. Een randomised controlled   
trial (RCT) is een voorbeeld van een experimentele onderzoeksopzet. 
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Interventiestudie 
Een interventiestudie is een experimenteel onderzoek waarbij men het effect van 
een experimentele interventie (bijvoorbeeld een geneesmiddel) onderzoekt. Een 
(randomised) controlled trial is een voorbeeld van een interventiestudie.  
 
Meta-analyse 
Een meta-analyse is een systematische review waarin de resultaten van een aantal 
vergelijkbare klinische studies worden gebundeld (gepoold) en herberekend. Hier-
door wordt het mogelijk om met een grotere nauwkeurigheid een schatting te 
doen van het effect van een interventie of behandeling. Zie ook pooling. 
 
Number Needed to Harm [NNH]  
Dit getal geeft aan hoeveel behandelde personen aanleiding geven tot één negatieve 
uitkomst (een schadelijke nevenwerking of dood) ten gevolge van een interventie.  
NNH = 1 / ARR (%) van de negatieve uitkomst x 100 
 
Number Needed to Treat [NNT] 
Dit getal geeft aan hoeveel personen moeten worden behandeld gedurende de be-
studeerde termijn om één extra geval van een bepaalde ziekte te genezen of te 
voorkomen.  
NNT = 1 / ARR (%) x 100 
 
Observationeel onderzoek  
Onderzoek waarbij geen interventie of experimentele behandeling wordt getoetst 
noemt men observationeel of beschrijvend onderzoek (bijvoorbeeld cohortonder-
zoek of case-control onderzoek).  
 
Peer review 
Hierbij beoordelen collega’s uit de eigen beroepsgroep op kritische wijze elkaars 
klinische handelen, onderzoeksprotocollen, of artikelen en abstracts die ter publica-
tie worden aangeboden aan tijdschriften of congressen. 
 
Placebo 
Een placebo interventie is een interventie die volledig gelijk is aan de te onderzoe-
ken interventie, maar zonder het werkzame deel. Wanneer het effect van een ge-
neesmiddel wordt onderzocht dient de placebo dezelfde kleur, smaak, grootte, con-
sistentie en wijze van toediening te hebben als het te onderzoeken geneesmiddel. 
Het placebo-effect is het effect dat niet verklaard kan worden op basis van een pa-
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thofysiologisch model, maar wordt toegeschreven aan andere factoren, zoals het na-
tuurlijke verloop van de klacht of aandoening, de arts-patiënt relatie, of de verwach-
ting (door patiënt, arts of onderzoeker) dat een bepaalde interventie of behandeling 
effect zal hebben. 
 
Pooling 
Onder pooling verstaat men het combineren van de resultaten van verschillende 
studies voor statistische bewerking in een meta-analyse om te komen tot een schat-
ting van het globale effect. Zie meta-analyse. 
 
Power 
De power is de mogelijkheid van een studie om de nulhypothese te verwerpen (en 
een eventueel werkelijk bestaande associatie aan te tonen). De power wordt be-
paald door een aantal factoren, zoals het voorkomen van de bestudeerde aandoe-
ning (de prevalentie), de grootte van het effect, de onderzoeksopzet en de grootte 
van de steekproef. Bij aanvang van een studie kiezen de onderzoekers zelf de ge-
wenste power om hiermee de benodigde steekproefgrootte te berekenen. Meestal 
wordt een power van 80% als minimale vereiste beschouwd. Dit betekent dat er 80% 
kans is dat de studie een effect kan aantonen.  
 
P-waarde 
De p-waarde is een maat voor de waarschijnlijkheid (probability) dat het gevonden 
resultaat van een onderzoek berust op toeval. De p-waarde is een maat voor de kans 
dat de nulhypothese ten onrechte is verworpen (en het gevonden verschil tussen 
onderzoeksgroepen dus in werkelijkheid op toeval berust). De p-waarde is een getal 
tussen 0 en 1 en wordt berekend met behulp van een statistische toets. Bij een p-
waarde van 1 kunnen we aannemen dat het gevonden resultaat op toeval berust. 
Met een p-waarde dichtbij 0 kunnen we ervan uitgaan dat de gevonden waarde een 
werkelijke associatie aanduidt. Gewoonlijk hanteert men p=0,05 als grens van statis-
tische significantie. Indien p < 0,05 dan is de kans dat het gevonden resultaat aan het 
toeval is te wijten (en we de nulhypothese ten onrechte verwerpen) kleiner of gelijk 
aan 5%, dit noemt men ‘statistisch significant’. Als een resultaat statistisch significant 
is, betekent dit niet automatisch dat het ook van belang is voor de patiënt.  
 
 
124      Verklarende woordenlijst 
Randomisatie 
Toewijzing door middel van randomisatie betekent dat iedere aan het onderzoek 
deelnemende persoon evenveel kans heeft om in een van de onderzoeksgroepen te-
recht te komen. Wanneer randomisatie op het niveau van groepen individuen (in 
plaats van aparte individuen) gebeurt spreekt men van cluster randomisatie.  
 
RCT Randomized controlled trial  
Zie clinical trial. 
 
Risico [risk, hazard] 
Een risico is een kans op een gebeurtenis. 
In een interventieonderzoek (RCT), waarin men het effect van een interventie on-
derzoekt op een bepaalde uitkomst (zoals bijvoorbeeld ‘verdwijnen van de koorts’) 
kan men de kans (het risico) op deze uitkomst berekenen voor de interventiegroep 
en de controlegroep.  
Het risico van de uitkomst in de interventiegroep is Ri = a / a + b. Het risico van die-
zelfde uitkomst in de controlegroep is Rc = c/c + d. 
 
Berekening van het risico in een RCT 
 
 Geen koorts Koorts 
Interventiegroep a b 
Controlegroep c d 
 
Relatief Risico (RR) 
Het quotiënt van twee (absolute) risico’s noemt men het relatieve risico RR (Ri/Rc). 
In een interventieonderzoek is dit relatieve risico een schatting van het aantal ma-
len dat de kans op een uitkomst (bijvoorbeeld ‘verdwijnen van de koorts’) in de in-




Het risicoverschil is het verschil tussen het risico van een uitkomst in de interven-
tiegroep en in de controlegroep (Ri-Rc). Bij afname van het risico noemt men dit   
risicoverschil absolute risicoreductie (ARR) (absolute risk reduction), bij toename 
absolute risicotoename (ARI) (absolute risk increase). Het absolute risicoverschil 
(ARR of ARI) is │Ri - Rc│.  
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Relatieve risicoreductie (RRR) 
Een relatieve maat voor risicodaling is de relatieve risicoreductie (RRR). Dit is de 
verhouding van het risicoverschil tussen de interventiegroep en de controlegroep 
ten opzichte van het risico in de controlegroep. Deze uitkomstmaat geeft de pro-
portionele reductie weer van het risico van een uitkomst door de interventie. De 
RRR wordt berekend als │Ri - Rc│/ Rc ofwel ARR / Rc.  
 
Statistische toetsen 
Wanneer men in een onderzoek een verschil tussen de onderzoeksgroepen vaststelt 
voor een bepaalde uitkomst, kan men met behulp van statistische toetsen nagaan 
hoe groot de kans is dat het gevonden verschil op toeval berust.  
 
Steekproef [sample] 
Een steekproef is een geselecteerde groep personen uit een populatie.  
 
Werkzaamheid [efficacy]  
De werkzaamheid (efficacy) van een geneesmiddel of interventie verwijst naar het 
gunstige effect ervan in optimale omstandigheden. De werkzaamheid wordt ideali-
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